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1. Motivation 
Medicine is always searching for new ways to improve patients’ conditions. The use of 
nanotechnology in medicine has recently opened a new field called “nanomedicine” which mainly 
aims to open new perspective of treatments and increasing therapeutic efficacy of existing 
therapies1,2. In the past years nanomedicine has gain attention all over the world and developed 
new approaches for medical treatments, as solubilization and targeting of cancer medicine or 
diagnostical tools. Different journals as “Nanomedicine – Nanotechnology, Biology and 
Medicine,” “International Journal of Nanomedicine” or “Nanomedicine” exclusively publish 
articles related with nanomedical topics, while other journals have subchapters dealing with the 
topic and development of nanomedicine. 
Nanomedicine generally describes the implementation and development of nanotechnology for 
medical applications3. It has a broad range of use, starting from solubilization of specific drug 
substances, to targeted-delivery systems in a body into a specific tissue or nanoelectronical 
sensors which are able to detect even the smallest quantities of desired molecules4. 
Nanomedicine aims to support and improve medicine by using properties of nanomaterials in 
order to diagnose or treat diseases at a molecular level5. Especially in cancer therapy 
nanomedicine has generated a lot of aspiration and visibility6. Nanomedicine for cancer therapy 
for example can improve the transport of a pharmaceutical active substances into the desired 
tissue, while decreasing the drug substances accumulation in non-target-tissue, additionally drug 
substances can be protected from degradation and cellular uptake is also facilitated7. Materials 
used for nanomedical approaches rang from natural lipids to modified proteins, antibodies or 
synthetic polymers. These materials are used to increase the efficacy of various treatments and 
therefore serve the patients well-being. 
To understand therapeutics activities on a nanoscale level and to use nanoscale objects for 
improving current therapies we focused in this thesis on two different approaches: 
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i.) Encapsulation of a photoactive molecule in a polymersome to investigate its ability 
to be used in cancer therapy (Figure 1). 
ii.) Encapsulation of an enzyme in a polymersome to study its activity under different 
crowding condition to mimic a cellular like environment. 
 
Figure 1 Schematic illustration of the conceptual Trojan horse like nanoreactor acting upon illumination as a source of reactive oxygen species inside a cancer cell. 
 
1.1. Encapsulation of photoactive molecules in a polymersome to 
investigate its ability to be used in cancer therapy. 
The classical method of nowadays cancer therapy are surgery, radiotherapy and chemotherapy. 
But cancer is still one of the main causes of death worldwide. A novel approach for cancer 
treatment is photodynamic therapy (PDT), which claims to be more precise and effective as the 
other methods. A real breakthrough in PDT was not achieved yet and a lot of hope is that 
nanomedicine can help to improve PDT in such a way that it can replace or support the classical 
methods. 
We wanted to create a polymersome encapsulating a photodynamic active molecule in high 
amount to serve as source of reactive oxygen species (ROS) on demand. The amount of ROS 
produced with such polymersome should be high enough to induce cell death while illumination 
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with low light dose. Additionally the polymersome should be stable to stay intact while blood 
circulation and cellular uptake. 
1.2. Encapsulation of an enzyme in a polymersome to study its activity under 
different crowding condition to mimic a cellular like environment 
Many diseases are caused on a malfunction of a cellular receptor or a failure of an enzyme. To 
understand the interaction and activity of these biomolecule many parameters as the Michaelis-
Menten constant are evaluated. The Michaelis-Menten constant which is reflecting the enzymatic 
activity is normally measured in optimized conditions for the enzymes which are not reflecting 
the real conditions they have to work on. 
We wanted to encapsulate an enzyme into a polymersome to simulate a compartmentalized 
space. As enzymes are also working not in bulk but in a closed environment as a cell, the approach 
to measure enzyme activity in polymersome would be closer to the real activity of enzymes. 
Additionally to embrace the fact that the enzymes are surrounded by many macromolecules 
while performing their catalysis we want also to evaluate the effect of macromolecule in the 
presence of the enzyme. The combination of encapsulating and a crowded environment would 
give a tool to measure enzyme activity in an artificial cellular like environment. 
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2. Introduction 
For both studies the use of a polymersome in the nanometer scale is essential to fulfill the set 
objectives. Polymersomes are artificial vesicles enclosing an aqueous cavity. They are formed by 
self-assembly of amphiphilic copolymers and can be produced in different sizes. Additionally, 
optimization on the vesicular membrane can help to adjust the polymersomes for different 
applications, e.g. as drug delivery vehicles or artificial organelle.  
2.1. Polymers 
Polymers are present in everyday life as of plastics such as polyethylene terephthalate (PET) in 
drinking bottles or polyethylene glycol (PEG) in shampoo or shower gel. Polymers are chemical 
compounds consisting of many repeating subunits called monomers, and they can exist as chains 
or in branched form. Besides synthetic polymers, natural polymers are essential in nature, as they 
are involved in different aspects of life on the molecular level. Deoxyribonucleic acid (DNA) and 
proteins for examples are two essential biopolymers and without them life would not exist in the 
form we know it. DNA and proteins consist of different subunits (monomers), while PET or PEG 
are built up of only on kind of monomer. Polymers consisting only of one type of repeating unit 
are called homopolymers, while polymers made from different building blocks are called 
copolymers. As polymers (homo and copolymer) are made up of typically more than ten repeating 
units and therefore have a high molecular weight, polymers are also classified as macromolecules.  
2.2. Block Copolymers 
Polymers that are used to form polymersomes are so called block copolymers and have an 
amphiphilic nature. A copolymer is a polymer resulting from more than one species of monomers8 
and can have a random order of the monomers. Block copolymers are macromolecules that 
contain different adjacent blocks of chemically distinctive monomers, different composition or 
different sequence distribution9. A block copolymer that consists of two types of monomers is 
called a diblock copolymer. When the block copolymer contains a hydrophobic (non-polar) and a 
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hydrophilic (polar) block it possess amphiphilic properties. Amphiphilic block copolymers can self-
assemble in aqueous solution into various supramolecular structures as micelles, rods, 
nanoparticles or polymersomes10,11. Different diblock copolymers are currently employed for 
polymersome formation: Poly(ethylene glycol)-b-polyactide acid (PEG-PLA), poly(ethylene 
glycol)-b-poly(ε-caprolactone) (PEG-PCL), poly(2-methyl-2oxazoline)-b-poly(dimethylsiloxane) 
(PMOXA-PDMS), poly(acrylic acid)-b-poly(styrene) (PAA-PS) or poly(N-vinylpyrrolidone)-b-
poly(dimethylsiloxane)-b-poly(N-vinylpyrrolidone) (PNVP-PDMS-PNVP)12. 
Triblock copolymers composed of an inner hydrophobic block attached to tow outer hydrophilic 
blocks are also used for polymersome formation. Examples of triblock copolymers used for 
polymersome formation are poly(2-methyl-2oxazoline)-b-poly(dimethylsiloxane)-b-poly(2-
methyl-2-oxazoline) (PMOXA-PDMS-PMOXA), poly(N-vinylpyrrolidone)-b-
poly(dimethylsiloxane)-b-poly(N-vinylpyrrolidone) (PNVP-PDMS-PNVP) or poly(oxyethylene)-b-
poly(oxypropylene)-b-poly(oxyethylene) (PEO-PPO-PEO)13. 
In this work two different types of triblock copolymer were used: PMOXA-PDMS-PMOXA and 
PNVP-PDMS-PNVP. Both triblock copolymers are linear polymers of the type ABA, where A is a 
hydrophilic part and B a hydrophobic block.  
PMOXA (the hydrophilic block) was shwon to be biocompatible and is mostly cleared from the 
blood stream after 24 h14. As degradation of PDMS in the body is slow, the clearance from the 
blood stream is linked to renal clearing. PDMS with lower molecular weight (around 5 kDa) can 
be removed from the body easily, while higher molecular weight PDMS has a tendency to 
accumulate in tissue14. The kidney has a molecular weight cut-off of approximately 30-50 kDa15, 
which explains that smaller the polymers are, the better they get cleared from the body, even if 
they are not biodegradable. Additionally, an advantage of PMOXA is that it is protein repellent16, 
which could be helpful for medical application to avoid an immune respond. Being protein 
repellent refers to the stealth properties of pegylated liposomes, which show better blood 
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circulation properties as non-pegylated17. The hydrophilic block of the polymer is in contact with 
the body fluids, PMOXA is preferred because of its non-ionic nature. In case of charged polymers 
the self-assembled polymersome could induce stronger immune response and therefore be less 
tolerable for medical applications. Additionally, it was shown that PMOXA can be used for medical 
applications18,19 and by end-functionalization additional properties e.g. cell targeting, can be 
introduced on the surface of the nanoreactors20. 
PNVP, another hydrophilic polymer, shows low toxicity even at high concentration of up to 1000 
µg/mL 21. PNVP was used as hydrogel for drug delivery for controlled release of different drug 
substances and it is used as excipient in the pharmaceutical industry21,22. PNVP can also be used 
as solubilization agent, due to its high water solubility, which then can be used to conjugate for 
example to a tumor necrosis factor-α(TNF-α) and then apply it intravenous to mice23. The PNVP 
conjugated TNF-α had extended blood circulation time compared to PEG-TNF-α and a 90-fold 
higher plasma-life than native TNF-α, which proves the biocompetability of PNVP in animals. 
PDMS, the hydrophobic block, which is used as constituent material for contact lenses or breast 
implants, is known to be biocompatible for a long time 24. Due to the good ability to form PDMS 
with accuracy of few nanometers 25, it has also been used for life-saving devices like pacemakers 
and is well-known in the medical field. PDMS is used in food industry as anti-foaming agent as 
additive E900 in concentrations up to 10 mg/L, which shows the good tolerability of PDMS in 
humans. Additional silicon based polymers also have a good bio durability helping to improve 
stability of self-assembled structures made of PDMS. PDMS has a low glass transition temperature 
(Tg= 146 K), which makes the PDMS chain flexible at room temperature or higher 26. Otherwise it 
is also stable under oxidative conditions and at higher temperatures, which partially explains the 
good chemical and biological stability 27-29. 
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The combination of one hydrophilic polymer (PMOXA and PNVP) with the hydrophobic PDMS 
allows to build an amphiphilic polymer, which can then be used for self-assembling nanomedical 
structures, since all of the polymers are known to be tolerable for medical applications. 
2.3. Self-assembly of amphiphilic block copolymer 
Amphiphilic block copolymers can, as already mentioned, self-assemble in aqueous solution into 
different structures. The obtained architecture is depending on several parameters such as 
concentration, molecular weight, geometry of the amphiphilic polymer or the ratio of the 
different blocks. The preferred structure we achieved to obtain are polymersomes and therefore 
the chosen triblock copolymers were optimized to form vesicular structures with an aqueous 
core. 
A similar behavior can be observed if lipids – naturally amphiphilic molecules – were dissolved in 
aqueous solution. Liposomes (from lipids and the Greek word soma (body)) were normally formed 
in aqueous solution, which is also the case for their synthetic analogue: the block copolymers30,31 
The self-assembly is mainly driven by non-covalent interaction (van der Waals forces) of the 
hydrophobic block. The aqueous phase favors the hydrophilic blocks and this triggers the self-
assembly process to avoid water contact with the hydrophobic part of the block copolymer32.  
Polymersomes can be generated in different sizes, from tens of nm up to µm - so called giant 
polymersomes33,34. The size of polymersomes is influenced by different parameters from the 
amphiphilicity of the polymers themselves, up to the preparation methods used to self-assemble 
the polymersomes. After the formation of the polymersomes their structure can be additionally 
influenced by external effect such as extrusion, sonication or freeze/thaw cycles35,36. The 
thickness and fluidity of the membrane depends on the character of the block copolymer. The 
thickness of the polymersome membrane is influenced by the molecular weight and the block 
number (tri- or diblock)37. Triblock copolymers with the same molecular weight as diblock 
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copolymers are forming thinner membranes and the higher the molecular weight of a block 
copolymer is, the thicker is the polymersome membrane. 
 
Figure 2 Higher molecular weight of the building blocks of a polymersome lea to increase stability and lower permeability compared to liposome (reprinted with permission of 30) 
2.4. Nanoreactors 
Polymersomes are usually employed for encapsulating of molecules. Further developments of 
polymersomes as nanoreactors, include the in situ production of active molecules. Nanoreactors 
combine the possibility to shield active molecules such as enzymes or proteins in nanometer size 
compartments, while preserving their functionality in situ 38. 
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2.5. Medical application of self-assembled structures 
2.5.1. Polymersomes 
Lipid based drug carriers are already approved for nanomedical purposes and in clinical trials and 
on the marked for several years. Examples for drug delivery system based on Liposomes are: 
Doxil, Visudyne, Thermodox or AmBisome39-42. Nowadays drug delivery systems are created by 
encapsulation of the drug substance in the aqueous core of a self-assembled structure38. The 
release of the drugs from the drug delivery system can be triggered by, pH, redox potential, light, 
magnetic field, differences in ionic strength or by instability of the system12. The advantages of 
higher stability of polymersomes over liposomes can be used to obtain more controlled release 
kinetics. Release that will start only after the delivery to the specific site would be an additional 
improvement of nanomedical fomulations. For example poly(butadiene-ethylene oxid) PB-PEO 
polymersomes were loaded with paclitaxel and they showed a steady release over 5 weeks at 37 
°C, correlated with reduced cytotoxicity43. Therefore, a long term drug releasing system can be 
achieved by choosing the appropriate polymer system. This is helpful to maintain a constant 
concentration of drug in the blood or at the targeted tissue (the so called ‘therapeutic window’) 
for a long time, without the requirement of administration of further doses. 
Fluorescently labeled poly(2-methacryloyloxyethyl phosphorylcholine)-poly(2-
(diisopropylamino)ethyl methacrylate) (PMPC-PDPA) polymers were used for example for in vivo 
studies, because they preferentially accumulate in tumor tissue, which may enhance 
polymersome based cancer therapy 44. The accumulation of a delivery cargo in tumor tissue is 
beneficial due to the reduction of the initial doses, related with lower side effects, as the drug is 
only released at the targeted site. Proper targeting and release of the active molecules in the 
desired location still needs to be improved for in vitro applications. Nevertheless, polymersomes 
have a broad range of biomedical applications in cancer therapy, diagnostics and vaccination38. 
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2.5.2. Nanoreactors 
Polymersomes are usually employed for targeted delivery of loaded active biomolecules. Further 
developments of polymersomes as nanoreactors, includ the in situ production of the desired 
active molecules. The greater stability of the nanoreactors compared to liposomes, is related to 
the polymer membrane and helps to maintain the encapsulated bio-active molecule inside the 
aqueous cavity and let the active molecule react in the presence of the substrate or when 
activated by an external trigger. To supply the bio-active molecule with starting materials for the 
reaction and to guarantee the escape of the newly formed molecules from the nanoreactor, a 
selective permeability of the nanoreactor membrane is required. Approaches to bring the bio-
active molecule together with its substrate are i.) using a substrate-permeable polymeric 
membrane or ii.) inserting membrane proteins into the polymeric membrane allow efficiently 
exchange of molecule across the polymer membrane45. PNVP-PDMS-PNVP block copolymers as 
well as PMOXA-PDMS-PMOXA are permeable for reactive oxygen species 46,47, while PMOXA-
PDMS-PMOXA is also able to reconstitute channel proteins as the outer membrane protein F 
(OmpF), the ferric hydroxamate uptake protein component A (FhuA), the receptor protein for the 
phage T6 and colicin K (Tsx) or the Aquaporin Z (AqpZ) to increase the permeability48. In all cases, 
small molecules can to be exchanged from the aqueous cavity of the nanoreactor to the 
nanoreactors environment and vice versa, while the bio-active molecule possesses a much higher 
molecular weight than the cut off of the channel protein cannot escape. 
The function of the nanoreactor depends on the nature of encapsulated bio-active molecule. For 
example by choosing the encapsulated enzymes, the nanoreactors can be used either to produce 
antibiotics in situ 49 or to act as an artificial organelle 50. Encapsulated photosensitizer can be used 
to generate a Trojan horse like nanoreactor for application in photodynamic therapy (PDT)51. 
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2.6. Characterization methods for polymersome and nanoreactors 
Due to their size in the nanometer range nanoreactors cannot be visualized and characterized 
with the classical optical methods. To obtain structural data from the nanoreactors and 
concentration of entrapped molecules different methods were used. 
2.6.1. Light scattering 
Light scattering (LS) uses the Brownian motion of particle in solution to determine their size. Small 
particles diffuse faster in solution compared to larger objects. To detect this motion a laser with 
constant intensity is used to illuminate the sample while at different angles changes in light 
intensity are measured. A small particle only causes a short change in intensity while a large 
particle causes a longer change. The fluctuation in light intensity over time can be fitted with an 
autocorrelation function and linked to a particle size. This kind of LS is also called dynamic LS. The 
particle radius which is determined by this technique is called radius of hydration. 
Different shaped particles have a different scattering profile at changing angles. If the average 
light intensity is recorded at different angles also a prediction on the particle shape can be done. 
The radius obtained by this technique (static LS) is called radius of gyration (Rg). Rg is the 
quadratic mean distance of the objects’ part from its center of mass. If both radii are correlating, 
then the measured object is of a vesicular structure 52. For nanoreactor this means that they are 
round shaped and have an aqueous core. 
2.6.2. Transmission electron microscope 
Due to the limitation of light microscopy regarding sub-visible particles, another microscope was 
developed, which uses electrons instead of light, because they have a much shorter wavelength 
than photons. The rule of thumb say that the resolution is maximum have of the wavelength 
(Abbe-limit).With normal light the smallest resolution would be around 200 nm, which is not 
enough to detect nanoreactors in the size range of 100 nm. A transmission electron microscope 
(TEM) uses electrons intensities to image samples, which gives a much higher resolution. The 
optics of a TEM is not done with glass lenses but with magnetic lenses to focus the electron beam. 
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The obtained image is a density profile of the samples as the denser a material is, the less electron 
can pass through and gives a gray colored image. Due to the resolution TEM can be used for 
structural observation of nanoreactors, but not for encapsulated dyes or molecules. 
2.6.3. Size exclusion chromatography 
Size exclusion chromatography (SEC) is a technique to separate differently sized objects in 
solution. It is used in the purification of polymers or proteins. The solution is eluted through a 
stationary phase based on small porous beads based on polymers. Theses polymer beads have 
pores of different sizes, where particles can be temporarily absorbed (Figure 4). Smaller particles 
are absorbed longer than particles larger than the pores. Therefore particles which are larger than 
the pore size will elute together through the column. The smaller particles will elute later, which 
makes it possible to separate for example polymersomes from proteins. 
In this process the biological activity of enzymes or protein will remain, as there is no chemical 
interaction between the stationary phase and the mobile phase. During this process, the samples 
gets diluted, which is the disadvantages of this process. 
 
Figure 3 Principle of size exclusion chromatography. Larger particles (e.g. polymersomes) will be separated from smaller objects (e.g. proteins) and will show up in the chromatogram at different time points53. 
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2.6.4. Spectroscopic methods 
As the polymers used for nanoreactor formation are not absorbing in the visible light range, 
encapsulated molecules which are absorbing in the visible range can be detected 
spectrophotometrically. Concentration of dyes as rose Bengal can be determined using law of 
Lambert-Beer. 
ܣ = ε݈ܿ 
Where A is the absorbance measured, ε is the extinction coefficient of the molecule, l the length 
of the pathway of the light and c the concentration of the measured molecule. 
Due to the scattering properties (see light scattering) of large objects as the nanoreactors, a 
background correction by measuring empty nanoreactors is needed. From the absorbance of the 
nanoreactor containing a dye molecule the background can be subtracted and the concentration 
of the dye molecules can be calculated. 
3. Polymeric nanoreactor to serve as Trojan horse for photodynamic 
therapy applications 
 
Photodynamic therapy is a new approach to treat the leading cause of death in developed 
societies- cancer. The current most widespread clinical strategies to treat cancer patient are: i.) 
surgery, ii.) radiation therapy and iii.) chemotherapy54. Surgery is the fastest method but it has its 
drawbacks if the tumor is located close to a sensitive area or if the tumor has already formed 
metastasis no complete treatment can be achived. Radiotherapy on the other hand, damages 
DNA, but leaks selectivity and therefore damage healthy neighboring cells or tissue. 
Chemotherapy suppresses cell growth or kills quickly dividing cells within the body. As a 
chemotherapeutic agents are distributed normally throughout the whole body undesired toxic 
side effects appear with this therapy, although the approach is advantageous in case of 
metastasized tumors. 
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In the past few years, the efficacy of chemotherapeutic agents has been improved by formulating 
them within nanocarriers, which improve the circulation time in the blood, by preventing renal 
clearance and non-specific uptake54. Additionally, an increased and targeted uptake into tumor 
tissue can be achieved by the enhanced permeability and retention effect (EPR). 
3.1. Enhanced permeability and retention (EPR) effect 
EPR - relies on the ability of tumor cells to grow faster and therefore on the fact that these cells 
require more nutrients and oxygen. Consequently the new formed blood vessels in tumor tissues 
show defects and larger openings that can allow the passage of structures with size around 200 
nm compared to healthy blood vessel7. Therefore nano-sized structures such as liposomes, 
polymersomes or micelles are favored in drug delivery by taking advantages of the EPR effect. 
Due to their size, these nanoparticles accumulate preferentially in the tumor tissue, while smaller 
molecules and larger assemblies do not profit from this size selection. The selectivity is only 
generated by the size and does not need an additional active targeting to the tissue. 
The selectivity is a crucial point of the treatment, as the more selective a treatment is, the less 
side effects can occur. Therefore novel methods for more selective treatment have been 
developed to fight cancer and improve patient’s conditions. To this point, photodynamic therapy 
(PDT) is a promising strategy as is has a dual selectivity, based on a photosensitizer exposed to 
light. Furthermore, the combination of nanomedicine with PDT even increases the selectivity of 
the therapy. 
 15  
 
Figure 4 Principle of the enhanced permeability and retention effect (EPR), where in tumor tissues the endothelia cells of the blood vessels are less densely packed as in healthy tissues, which allows particles around 200 nm to diffuse easily into tumor tissue (reprinted with permission of 7) . 
3.2. Photodynamic therapy (PDT) 
PDT uses the ability of excited photosensitizer to transfer energy to molecular oxygen returning 
to the unexcited state55-58. In this way molecular oxygen, is converted to ROS (cytotoxic reactive 
oxygen radicals) which will induce - apoptosis and cell death. Compared with classical 
chemotherapy PDT has the advantage of a photosensitizer that has normally minimal toxic effect 
in the absence of light, even if accumulated in non-specific tissues54. Additionally due to the low 
toxic side-effects of PDT, PDT needs an external trigger (light) to be activated and therapy can be 
repeated as needed. 
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Figure 5 Photodynamic therapy needs three components (light, photosensitizer and oxygen). Light can activate from the ground state to an excited state a photosensitizer at a specific wavelength of light. The energy can be transferred to oxygen, which is than transformed into reactive oxygen species, which lead to cellular toxicity. 
To date, only few PDT based therapy formulations have been marked (e.g. Photofrin® Visudyne® 
or Foscan®). PDT is limited with respect of targeting and penetration depth. UV light has a 
maximum penetration depth of 1 mm, while a wavelength of 630 nm can reach a maximum depth 
of 6 mm into the skin59. Therefore most of the marked PDT treatments are used in skin cancer 
therapy, when the tumor tissue is not large and easily accessible to light. 
Properly delivered and activated photosensitizer can cause all three forms of cell death 
(apoptosis, necrosis, and autophagy). Photosensitizer can act on different organelles, such as 
mitochondria, endoplasmatic reticulum, Golgi apparatus or directly on the plasma membrane60. 
The stimulated production of reactive oxygen species lead to an increase of the oxidative stress 
that will induce the oxidation of enzymes and  interruption of repair mechanisms, which ends in 
cell activated apoptosis60. The cellular response will be influenced by several different factors, 
such as photosensitizer, localization, experimental model and light dose to induce multiple 
metabolic changes and cell death mechanism.  
The drawback of current photosensitizers is that most of them are hydrophobic and had to be 
formulated for administration so that the photosensitizer reaches the target tissue61. The help of 
nanomedicine can help to overcome this problem and may even use the EPR effect for passive 
targeting7,62. Additionally, drug delivery systems normally have the advantages of causing lower 
side-effects. Nanomedicine drug delivery system can also be compared with the legendary Trojan 
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horse, with which the Greek soldiers were delivered into the city walls of Troy, buried a huge 
wooden structure. A more modern Trojan horse is a computer virus embedded within a friendly 
looking program. The design of a Trojan horse for PDT has to be stable at least till it is delivered 
into the cells and be activated upon arrival51 [Baumann_2013]. 
 
Figure 6 Photodynamic therapy is used for targeted cancer therapy; thereby the formulated photosensitizer is injected into the patient and delivered to the tumor tissue. Activated by external light the produced ROS is selectively destroys the tumor tissue. 
 
3.4. Conjugation of photosensitizer with bovin serum albumin (BSA) 
For the photodynamic therapy experiments Rose Bengal (RB) was chosen as photosensitizer, due 
to the high photodynamic activity, good quantum yield, absorption in the visible region, and 
inexpensiveness63,64. The high quantum yield of Rose Bengal helps to keep the amount of 
photosensitizer low. But on the other side Rose Bengal has a tendency to interact with the 
polymeric membrane so in order to avoid this kind of interaction the solubilization of RB was tried 
in such a way its efficacy was maintained. 
A method to increase the solubility of RB without any chemical modification is conjugation with 
bovine serum albumin (BSA). Additionally the conjugation to a protein will help to avoid 
interaction of the photosensitizer with the polymersome membrane, as PMOXA – the hydrophilic 
part of the nanoreactor membrane – is protein-repellent. If no interactions between the 
membrane and the photosensitizer happen the system can be better controlled in terms of 
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stability and purity. The conjugation between RB and BSA is known to be a stable hydrophobic 
interaction65, leading to a shift in the maximum absorbance of RB from λ=547 nm to λ=559 nm 
(see figure 4) 66. Depending on the ratio of RB to BSA the maximum absorbance peak can vary 
between these values, while higher BSA content leads to red-shifted of spectra. An optimal ratio 
of RB to BSA was found to be 1:1, while for the experiments a small excess of BSA was used, which 
should guarantee that no free RB is present in the stock solution used for encapsulation. With the 
use of BSA another problem appeared. Higher concentration of BSA can influence the self-
assembly process and therefore a maximum concentration of BSA (10 mg/mL) was found to be 
the upper limit. At this concentration the self-assembly process of the nanoreactors was not 
affected. 
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Figure 4 UV-Vis spectrum of rose Bengal (black line), and rose Bengal-BSA conjugates after purification with a HI-Trap column (red line) in PBS buffer at room temperature. 
 
3.5. Polymer synthesis 
The used PMOXA-PDMS-PMOXA polymers were synthesized by a polycondensation reaction of 
PDMS monomers followed by a cationic ring opening polymerization with 2-methyl-2-oxazoline 
 19  
previously described by Meier et al. 67. A final quenching of the reaction with KOH solution in 
methanol led to a hydroxyl-terminated triblock-copolymer. 
From the 1H NMR, the integrated peaks could be used to determine the composition of the 
triblock polymer, giving the different block length of the PMOXA and PDMS blocks. The obtained 
triblock polymer characteristics are presented in table 1. 
 
Figure 5 1H-NMR spectrum of PMOXA10-PDMS87-PMOXA10 polymer. 
The synthesis of PNVP-PDMS-PNVP polymer was performed according with the method already 
described in the literature by Simionescu and co-workers68. The resulting block length of the 
polymer are presented in table 1  
 
 
 
 
 
Table 1 Triblock copolymer used for the encapsulation of RB-BSA. The polymers were chosen, as these kinds of polymers are known to be permeable for ROS [REF]. 
Polymer name Composition Mn /(GPC) reference A1 PMOXA10-PDMS87-PMOXA10 8352 20 A2 PMOXA14-PDMS33-PMOXA14 4720 Polymer source P3691A 
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A3 PMOXA6-PDMS44-PMOXA6 4555 69 B1 PNVP11-PDMS17-PNVP11 2360 47 B2 PNVP17-PDMS17-PNVP17 4200 47 B3 PNVP30-PDMS37-PNVP30 6160 47  
3.6. Formation of polymeric vesicles 
Polymersomes can be prepared in a similar way as the lipid analogues, the liposomes. Three main 
techniques can be used: i.) direct dissolving, ii.) co-solvent method and iii.) film rehydration. If a 
polymer is directly dissolved in aqueous media without any pre-treating, then this method is 
called direct dissolving. Depending on the hydrophobic properties of the polymers, not all 
polymers can be used for the direct dissolving method, as some of the polymers only swell but do 
not reassemble into a more complex architecture such as  polymersomes. 
The co-solvent method is performed by dissolving the polymer in a small amount of solvent (e.g. 
EtOH) and then adding it drop-wise to an aqueous solution under stirring. The added solvent can 
be removed after self-assembly by evaporation. 
The optimal method to form polymersome was in our case the film rehydration method 51. In a 
first step the block-copolymer is dissolved in an organic phase (e.g. EtOH) that is removed under 
reduced pressure. Due to the slow removal of the organic phase a thin film of the polymer is 
formed on the bottom of the flask, which increases the surface for rehydration of the polymer.  
Finally the rehydration of the polymeric film was performed by adding the desired molecule 
aqueous solution and stirring. The speed of stirring was adjusted so that the stirring bar did not 
come in contact with air so as to avoid bringing oxygen into the system, which could lead to 
oxidation of the active molecule and therefore to a reduced activity of the nanoreactor. In order 
to help the mechanical detachment of the polymeric film the glass flask was tilted manually, so 
that the stir bar came into contact with the whole polymer film. The self-assembly process was 
normally done overnight at room temperature. 
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3.7. Encapsulation of RB-BSA into polymersomes 
To produce a nanoreactor permeable to reactive oxygen species (ROS) different triblock 
copolymers were used. Both, PMOXA-PDMS-PMOXA and PNVP-PDMS-PNVP polymers were 
chosen due to their known permeability to ROS47,70. Different block lengths of the polymer were 
used (see table 1) to obtain a nanoreactor optimized from encapsulation efficiency and uptake 
behavior into cancer cells. 
The nanoreactors were prepared by the film rehydration method at room temperature overnight 
under darkness. The preparation in the dark was to preserve the stability of the photoactive RB-
BSA conjugate. As the film rehydration led to a large size distribution of polymersome, the 
nanoreactors were extruded several times through 0.2 µm filters, to obtain a narrow size 
distribution of the nanoreactors. Additionally smaller vesicles are known to support the enhanced 
permeability and retention effect7. This effect could help in further studies targeting tumor tissue, 
without further modification of the nanoreactor. 
As the encapsulation is a statistical process, not all active molecules will be encapsulated during 
the film rehydration. In order to remove free RB-BS, size exclusion chromatography was used. 
The chosen size exclusion chromatography (SEC) gel (Sepharose 2B) is optimal to separate 
proteins such as BSA. The separation was detected with a UV-detector at the end of the column 
and the obtained chromatogram showed two separate peaks: one for free and one for 
encapsulated RB-BSA (See figure 6 A).  
A sample of purified nanoreactors was applied on a SDS-PAGE and no free BSA was detected. This 
proved additionally that no interaction between the polymer membrane and the RB-BSA 
conjugate occurred, as empty nanoreactors were incubated as a control for one hour with RB-
BSA at room temperature. After that chromatographic separation of the nanoreactors fractions 
was performed by SEC - no RB-BSA could be detected after separation indicating that RB-BSA does 
not attach on the surface of polymersomes. 
 22  
 
Figure 6 UV (280 nm) chromatogram of the process that separates RB-BSA nanoreactors (a), and non-encapsulated RB-BSA (b). B) SDS PAGE of the fractions corresponding to Figure S2 A). 
The influence of encapsulation on the absorbance behavior was investigated by using the 
fluorescence properties of RB, which is also present in the conjugated form. While the non-
conjugated RB has an emission maximum of 563 nm if excited with 543 nm light the conjugated 
form has an emission maximum around 578 nm (see figure 7). The presence of polymer vesicles 
does not influence the fluorescence emission spectrum of RB-BSA, even if encapsulated. This 
indicates that the polymer membrane is not a barrier for the light and will not limit the efficiency 
of the photodynamic activity of the nanoreactors.  
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Figure 7 Emission spectra of RB (black line), RB-BSA conjugate (red line), empty vesicles in presence of RB-BSA (green line) and nanoreactors with RB-BSA inside (blue line) measured in PBS buffer (excitation at 543 nm). 
 
3.8. Nanoreactors characterization 
Purified nanoreactors were characterized from their encapsulation efficiency and size. 
Additionally, transmission electron microscopy (TEM) images were taken to confirm their 
morphology and size.  
3.8.1. Encapsulation efficiency  
To assess the encapsulation efficiency of the nanoreactors the maximum absorbance (λ= 559 nm) 
of a dilution series of known RB-BSA concentrations was measured spectrophotometrically and 
compared with the nanoreactors encapsulating RB-BSA after purification. Due to the scattering 
of the polymersome itself at this wavelength, spectra ranging from 400 nm to 600 nm were 
recorded and background correction was done. The background correction was defined for each 
measurement separately. With this method we ensured that the influence of the polymersome 
scattering was negligible. In order to estimate the encapsulation efficiency the amount in percent 
of the initial RB-BSA concentration was taken and additionally the dilution-factor was applied. 
Encapsulation efficiencies of 1.5 % to 13 % for different polymers were obtained (see table 2). 
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These values are similar to other polymersomes encapsulation proteins with comparable 
molecular weights49,71. 
3.8.2. Light scattering 
Using static and dynamic light scattering the radius of gyration (Rg) and the radius of hydration 
(Rh) of the nanoreactors were determined. As the nanoreactors were extruded through a 0.2 µm 
filter membrane the expected radii were around 100 nm. With radii (Rg) ranging from 103 nm to 
149 nm, the results are all above the expected value. Probably due to a slight deformation of the 
polymer membrane. The same behavior was observed by extruding the A1 polymer through 
smaller pores (0.1 µm and 0.05 µm). The discrepancy between the pore size of the filters and the 
measured size is larger the smaller the pore is. As the polymer membrane has a thickness of 
approximately 14 nm and a certain curvature of the membrane, the nanoreactors are more stable 
around 200 nm.  
 
 
Figure 8 Static light scattering Gunier plots of A1 nanoreactors: A) freshly prepared RB-BSA nanoreactors, B) RB-BSA nanoreactors after one month, C) freshly prepared empty vesicles, and D) empty vesicles after one month. 
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Figure 9 Berry-Plots of (a) A1-50- (b) A1-100- (c) A2- and (d) A3- nanoreactors without illumination 
 
The ratio of both radii (Rg/Rh), if equal to 1, indicates a the formation of hollow spherical 
structures52. Additionally the second virial coefficient (A2) is almost zero, indicating that no long-
range interaction in the measured concentration range occured. 
The obtained data for the Rg and Rh are comparable between nanoreactors with and without 
encapsulated RB-BSA (see table 2). The differences were within the error range of the 
measurement. Illumination with light did not induced changes in the morphology of the 
nanoreactors, which support their used for medical applications. Similar PMOXA-PDMS-PMOXA 
vesicles were also stable over several hours in blood plasma72, which makes them also suitable 
for in vivo application. 
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Table 2 Nanoreactor characteristics: Rg and Rh were determined using dynamic and static light scattering. The encapsulation efficiency was a results of absorbance measurement of the purified nanoreactors compared to the unpurified nanoreactors. RB-BSA conjugates per vesicles is based on a mathematic model (see materials and methods), to give ab impression of the amount of photosensitizer per nanoreactor. 
Sample name Rg [nm] Rh [nm] Encapsulation 
efficiency [%] 
RB-BSA 
conjugates per 
vesicles 
A1-200 103 109 13.0 22 
A1-100 70 74 13.0 7 
A1-50 55 60 13.0 4 
A1-200 empty 107 112 -- -- 
A2 89 95 2.3 2 
A3 149 157 12.5 61 
B1 120 118 1.5 3 
B2 112 121 3.8 13 
B3 118 129 8.6 23 
 
3.8.3. Transmission electron microscopy (TEM) 
 In order to characterize the morphology of the formed self-assembled structures TEM was used. 
To induce a better contrast, before TEM measurements the samples were negatively stained with 
uranyl acetate. 
On TEM micrographs collapsed spherical objects are visible, similar with those also observed by 
atomic force microscopy (AFM)73. The sizes of the collapsed structures are around 200 nm as 
shown by light scattering. The nanoreactors are separated from each other, which supports that 
no long-range interaction between nanoreactors can be seen.  
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Figure 10 A and B) ABA-1 nanoreactors after 200 nm extrusion, showing the usual collapsed spherical structure. Besides the formed nanoreactors also a few worm like micelles were formed, but due to their size they probably have not contributed to the encapsulation of RB-BSA. C) A3 micrograph of A3 nanoreactors with encapsulated RB-BSA. 
 
3.9. Nanoreactor activity 
In order to quantify the ability of the nanoreactors to produce ROS under illumination a scavenger 
system for radicals was used. The scavenging molecules 2,2,6,6-tetramethyl-4-piperidinol (TMP–
OH) and 5,5-dimethyl-1-pyrroline N-oxide (DMPO) were used to trap species produced by the 
photo-activity of rose Bengal and RB-BSA. The spin trap TMP-OH is a diamagnetic molecule and 
therefore not detectable with electron spin resonance (ESR). If reacted with reactive oxygen 
species it will be transformed into a paramagnetic molecule 4-hydroxy-2,2,6,6-teramethyl 
piperidin-1-hydroxyl (TEMPOL), detectable by ESR. As the nanoreactors are impermeable to most 
molecules except ROS the scavenger molecule cannot enter inside the nanoreactor. Therefore 
the radicals detected are the ones which cross the membrane of the nanoreactors and are of 
therapeutic value. 
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Figure 11 2,2,6,6-tetramethyl-4-piperidinol (TMP–OH) is acting as a spin trap and will be transformed in the presence of radicals and singlet oxygen to 4-hydroxy-2,2,6,6-teramethyl piperidin-1-hydroxyl (TEMPOL). As TMP-OH is ESR inactive (not paramagnetic) the new formed product TEMPOL is paramagnetic and can be easily be detected via ESR. 
The ability to produce ROS is dependent on the quantum yield of RB. The conjugated BSA and the 
shift in the absorbance could have an influence on the quantum yield. Studies on the photo 
activity by conjugating RB to peptides show no significant loss of photo activity65.  
To compare the activity of RB and the BSA conjugated RB, two solutions with both the same 
concentration of RB were mixed with the scavenging molecule and then illuminated with artificial 
daylight. After 0 min, 5 min, 10 min 15 min and 20 min the concentration of the formed ESR active 
molecule was measured.  
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Figure 12 Development of the integrated ESR signal while illumination with withe light. ■ (black) Increasing signal of formed ESR active TEMPOL in the presence of illuminated RB. ● (red) detected signal of the same concentraƟon of RB but conjugated to BSA. ▼ (green) ESR signal development of RB-BSA encapsulated in A1-200 polymersomes adjusting the overall concentration of RB-BSA to the free condition. ► (olive green) Control experiment using empty nanoreactors in the presence of TMP-OH and light. 
For pure RB the signal of the spin trap increased faster than for the conjugate. At the end the RB-
BSA conjugate showed about 70 % of the photo activity of pure RB in PBS buffer. The loss of 
activity can be explained by the red shift and the large BSA molecule conjugated to RB. The red 
shift implies a lower energy that can be absorbed by RB, which can influence the photo activity. 
Moreover, additional BSA conjugated to RB can absorb some of the produced ROS and therefore 
influence the measured activity. Nevertheless, due to the initial high photo activity of RB-BSA 
even 70% of its total activity could be expected to be high enough for photodynamic therapy. 
As encapsulation of RB-BSA in nanoreactors was found to lower activity, both free and conjugated 
RB containing the same RB concentration encapsulated into nanoreactors were mixed with the 
spin trap and further illuminated. No difference between free and RB-BSA conjugated 
encapsulated in nanoreactors was observed. As the polymeric PMOXA-PDMS-PMOXA membrane 
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is known to be permeable to ROS the encapsulation had no effect on the photoactivity. As empty 
nanoreactors do not absorb light around 550 nm – 560 nm the full energy of the light can be 
transferred to the RB-BSA conjugate. 
To investigate the nature of obtained ROS species the obtained signal was simulated and was 
shown to be composed by the contribution of a signal characteristic for TMP-OH was TEMPOL (g 
= 2.0055, aN = 17.13 G). – and a small fraction of 4-oxo-2,2,6,6-teramethyl piperidin-1-oxyl 
(TEMPONE) (g = 2.0054, aN = 16.13 G) due to the attack of O2- on TEMPOL. This suggests that 
different ROS molecules are produced in the nanoreactors and are able to diffuse out from there. 
As by conjugation and encapsulation in nanoreactors only 30% of RB activity was lost comparing 
to pure RB, encapsulated RB-BSA seems to be an interesting candidate for photodynamic therapy 
treatment. 
3.10. Cytotoxicity of RB-BSA containing nanoreactors 
To prove the biological compatibility and quantify the influence of nanoreactors on cell viability, 
HeLa cells were incubated with RB-BSA containing nanoreactors. HeLa cells are culturable cervical 
cancer cells that are well established in basic research74. Due to their fast growing and unspecific 
nature they are ideal for a first indication of cytotoxic effect of the nanoreactors. The toxicity was 
assessed by incubating HeLa cells with RB-BSA nanoreactors for 24 h. Different concentrations of 
A1-200 nanoreactors were incubated with HeLa cells and their viability was measured after 24 h 
with a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay. To avoid the production of ROS, which can maybe influence the viability 
results, the nanoreactors the manipulation of the cell culture was done in the dark. Surprisingly 
empty and loaded nanoreactors shows similar viability data, indicating that small doses of light 
did not induce cell death. The viability of the cells remained above 90 % up to a polymer 
concentration of 300 µg/mL, which considered a high dose in photodynamic therapy. The good 
biocompatibility is in agreement with other viability tests of similar nanoreactors. 
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RB is known to be toxic and therefore not extensively evaluated as a photosensitizer 75. But as RB-
BSA is only encapsulated in the nanoreactor and not attached on the membrane it was not 
expected to add any additional toxicity. The low toxicity observed can be obtained from inhibition 
of growing of the cells and RB-BSA induced. This also clearly indicates that the encapsulation in 
nanoreactors prevent toxicity based on RB-BSA.  
3.11. Cellular uptake studies  
It is important for the efficiency of photodynamic therapy that it is active in vitro and not only in 
situ. To be an efficient system, the nanoreactor has to be able to enter into the cells, as inside the 
cell the damage generated by ROS have a higher impact than in bulk. Therefore the uptake into 
cells without degradation or damage of the photosensitizer is an essential step for the action of 
the nanoreactor. 
In order to assess the ability of nanoreactor to be taken up by cells the fluorescence property of 
RB was used. RB is slightly fluorescent76,77 and can be excited with a 543 nm laser and detected 
by flow cytometry and fluorescent microscopy. 
To prepare cells for uptake experiments they were first cultured for 24 h without nanoreactors. 
Nanoreactors were then added and the cells were cultured for an additional 24 h. Nanoreactors 
were not sterilized any further for use, as they were already extruded through 0.2 µm filters. An 
additional sterilization step was avoided as it could also have induced changes in the structure of 
the nanoreactors or affect their integrity. 
To investigate if the nanoreactors were taken up by the cell and not just attached to the cellular 
surface, cells were washed before the experimental read-out several times with PBS to remove 
nanoreactors sticking to the outside of the cells. The cell membrane and the DNA of the HeLa cell 
were additionally stained with flourophores outside of the excitation and emission wavelength of 
RB-BSA. This staining of the membrane also helped to localize the cytosol of the cell and therefore 
get an impression of where the nanoreactors were localized after uptake. The stained DNA shows 
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indirectly the nucleus of the cell. As transport across the nucleus membrane is highly regulated, 
nanoreactors were not expected to enter the nucleus as, being around 200 nm in diameter, they 
are too large to enter. 
Confocal laser scanning microscope (CLSM) images only show a cross section layer of the cells 
containing uptaken dye (nanoreactor). The fluorescent signal of the photosensitizer was 
therefore expected to be enclosed within the boundary signal of the cell membrane, but not 
overlapping with the DNA (nucleus) signal. This could be clearly seen in figure 15, where overlying 
images of all three channels (nucleus, cell membrane and nanoreactors) are separated in space. 
Therefore, results were compatible with uptake into the cytosol. Similar systems have already 
been shown to be taken up by cells and be active within the cell 71. 
Because with CLSM only qualitative cellular uptake could be seen, flow cytometry measurements 
were conducted to get a more quantitative readout. A flow cytometer has a flow cell, where HeLa 
cells can pass through individually and different light scattering and fluorescence data of the cells 
can be collected. A forward scattering detector (FSC) is able to assess the cell size, while a 
sideward scattering unit (SSC) gives details about the complexity of a cell, including information 
on nanoparticle uptake. 
Forward scattering helps to detect cells and ignores other particles flowing through the detector. 
Therefore if a nanoreactor outside a cell would pass the detector individually it could be excluded 
from the measurement. The SSC in our case detected if cell membranes were still intact. A high 
signal of sideward scattering indicated that the cells were undergoing apoptosis. With the help of 
this signal we were able to assess if the cells measured were healthy and exclude the unhealthy 
cells from the fluorescent measurement. Only a few cells (less than 5%) had to be excluded from 
the measurements, indicating a high level of viability, as already evaluated with the MTS assay. 
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The fluorescent signal of RB-BSA was measured simultaneously with the sideward scattering 
signals giving a quantitative amount of nanoreactors taken up into healthy cells. As control 
measurements, cells not pre-treated with nanoreactors were measured and taken as a reference 
for the fluorescent signal shift in the as ahistogram and parameter for optimal uptake (see figure 
13). The fluorescent signal of 20’000 viable cell was measured to get good statistics of cellular 
uptake. 
The uptake behavior of the different measured nanoreactors can be seen in figure 13, where the 
counts were normalized and in which a clear difference in the fluorescence intensity can be seen, 
indicating an internalization of the nanoreactors into the cells. The PNVP-PDMS-PNVP 
nanoreactors showed lower uptake that the PMOXA-PDMS-PMOXA based nanoreactors. The 
uptake behavior was only little different in the case of A1- and A3-nanoreactors. As A1 
Figure 13 Flow cytometry: cells incubated with A1-200 (green), A3- (yellow), B2- (blue) and B3- (red) nanoreactors and control cells (black). These nanoreactors were tested as they had the best encapsulation efficiency and therefore could bring a higher density of RB-BSA inside cells. The shift towards higher fluorescent intensity indicates a higher fluorescent signal detected in the cells. Therefore A1-200 and A3 nanoreactors were the most efficient vectors for entering HeLa cells.  
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nanoreactor had less RB-BSA per nanoreactor the efficiency in nanoreactors uptake was probably 
better with the A1 nanoreactors.  
As the uptake can also be size dependent78-80, different sized nanoreactors based on the A1 
polymer were prepared to explore wheter the size of the nanoreactor could help improve the 
cellular uptake. Therefore A1-200 nanoreactors where further extruded through a 0.1 µm pore 
size membrane and a part of this solution also through a 0.05 µm pore size membrane. The 
characteristic of these nanoreactors can be seen in table 2. 
Measuring the fluorescence intensity by flow cytometry with cells incubated with the different 
extruded PMOXA-PDMS-PMOXA based nanoreactors (A1 polymer), no significant difference in 
the fluorescent signal (uptake of nanoreactor) could be seen. This suggests that the size in the 
range of 50 nm to 200 nm did not influence uptake. 
 
Figure 14 Flow cytometry was used to determine the fluorescence content of cells treated with A1-200(blue), B1-100 (green) and A1-50 (red) nanoreactors loaded with RB-BSA and (black) control cells. 
 
3.12. Stability studies of nanoreactors 
Both CLSM experiments and flow cytometry measurements showed that RB-BSA was successfully 
internalized in HeLa cells with the help of nanoreactors. To prove the integrity of the nanoreactor 
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system inside cells after uptake, doxorubicin (DOX) was encapsulated in nanoreactors as a control 
instead of RB-BSA. DOX is used as chemotherapeutic drug81,82 and intercalates with DNA when 
freely taken up by cells82. Therefore an overlay of the DNA staining signal with the fluorescent 
signal of DOX would be expected in the case of rupturing nanoreactors inside the cells. In contrast, 
if the nanoreactor were taken up as a whole and did not degrade after uptake, the fluorescent 
signal should be exclusively detected, outside of the nucleus and, as-with RB-BSA in the cytosol 
of the cells. Additionally DOX is a toxic substance, which would lead to cell death, which would 
also be detected by CLSM, as cells would not be able to stretch anymore. 
 
Figure 15 HeLa cells incubated in the presence of doxorubicin loaded nanoreactors. The upper left image shows the fluorescent channel of the DNA staining dye (Hoechst 33342 10 µg ml-1). In the upper right corner the membrane staining is visible, as the borderline of the HeLa cells (Cell Mask Deep Red 5 µg ml-1) Lower left micrograph is showing the fluorescent doxorubicin signal, while the lower right images is the merge of all three individually scanned images. These images show that doxorubicin (encapsulated in the nanoreactors) appeared within the plasma membrane of the cell and not in the nucleus. This finding emphasizes that the nanoreactors can enter the cell, without leaking their doxorubicin content. 
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Nanoreactors containing DOX were incubated with HeLa cells and after 24 h prepared for CLSM 
measurements. The fluorescent signal from DOX was detectable inside the cell, but was not found 
to overlay with the fluorescent signal of the DNA staining. This indicates that the fluorescent DOX 
loaded nanoreactors were taken up by HeLa cells, but that DOX was nto further transported into 
the nucleus. That DOX remained in the cytosol indicates that the nanoreactor system was still 
stable and no leakage of the encapsulated molecules happened during cellular uptake. This 
observation is in good agreement with other studies, showing that PMOXA-PDMS-PMOXA based 
nanoreactors can keep their architecture inside the cell for more than 48 h 71. This long stability 
in vitro can also promote nanoreactor accumulation in tumor tissues after administration. 
The stability of the nanoreactors in presence of light was evaluated by light scattering (LS) and 
TEM micrographs of A1-200 nanoreactors. LS data show that the size of nanoreactors did not 
change after illumination (table 3). The ratio between Rg and Rh was around 1 indicating that these 
measured self-assembled structures were spherical and had an empty core. TEM micrographs 
showed typical collapsed structures of round objects (see figure 17) – as with nanoreactors left 
untreated with light - indicating that the morphology does not change upon illumination. In case 
of loaded RB-BSA nanoreactors, we expected a different reaction as along with the illumination 
the generation of ROS would start. Still, LS and TEM data indicated that the size and morphology 
of the nanoreactors was not changed during the production of ROS. The combined stability test 
of in vitro ROS production was not assessed, but it was assumed that the nanoreactors are also 
stable under irradiation in vitro. 
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Figure 16 Berry-Plot of A1-200 nanoreactors after illumination. 
Table 3 static and dynamic light scattering data for A1-200 nanoreactors with illumination.  
 Rg Rh Rg/Rh Mw g mol-1 A2 mol dm3 g-2 A1-200 101 ± 4 nm 106 ± 2 nm 0.95 1.826x109 3.665x10-10  
 
Figure 17 TEM micrograph of nanoreactors after illumination with 90 J/cm2 
3.13. In vitro ROS production 
After proving that the nanoreactors were taken up as a whole by HeLa cells their functionality 
inside cells was tested. First, light induced toxicity of nanoreactors was assessed after cellular 
uptake of the nanoreactors. HeLa cells were incubated with 100 µg/mL A1-200, A1-100 and A1-
50 nanoreactor for 24 h and washed with PBS, as it had beed done for MTS viability 
measurements, CLSM and flow cytometry. After adding fresh media, the cells were illuminated in 
96-well plates from the bottom for 0-30 min with an artificial daylight lamp with an intensity of 
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90 J/cm2. This light intensity is in the normal range in medical use of PDT 83,84, but can also be 
increased if needed. The use of a specific lamp in the optimal range for ROS production of RB-BSA 
(530-560 nm) would be beneficial for a medical application.  
The viability readout was determined by using MTS assay. Controls with illuminated cells with no 
nanoreactors, did not show a reduced viability of the cells after illumination, whereas the cell pre-
treated with A1 based nanoreactors showed a reduced viability after 30 min. The viability seemed 
to be decreas linearly with time and reached after 30 min approximately a viability of 50 – 60 % 
compared to the control cells. The larger nanoreactors A1-200 had a better performance in 
inducing toxicity than the smaller A1-100 and A1-50 nanoreactors. The induced toxicity was 
explained by ROS production inside the cell, which was activated by the external light. As only in 
the presence of light the nanoreactors induce increase in toxicity, we could control the degree of 
toxicity with the light dose as well by controlling the illumination time. 
 
Figure 18 MTS assay of HeLa cells incubated with A1 based nanoreactors of different size illuminated for different periods of time. ▼(green) control cells without nanoreactors,▲ (blue)  A1-50-based nanoreactors, ● (red) A1-100 –based nanoreactors, ■ (black) A1-200-based nanoreactors. The viability of the control cells did not change upon illumination, whereas within 30 minutes of illumination up to 50 % of the viable cells died in case of A1-200 nanoreactors. 
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To investigate the level of ROS which is produced in cells an experimental setup was established 
using a non-paramagnetic compound, which is activated only inside cells by esterases. In the 
presence of esterases the non-paramagnetic compound is transformed into a radical scavenger 
molecule. The scavenger molecule can then be transformed further in the presence of free 
radicals into a paramagnetic compound which can be detected by ESR. 
1-Acetoxy-3-carbamoyl-2,2,5,5-tetramethylpyrrolidine (ACP) is cell permeable and has an ester 
bond, which can be cleaved by esterases- only after uptake by cells. The deprotection of ACP leads 
to a cyclic hydroxylamine, which turns to a nitroxide radical in presence of ROS. To measure the 
intracellular level qualitatively, control cells were incubated with ACP and the nitroxide level was 
determined by ESR. A characteristic signal of a nitroxide radical (aN = 16.1 G) was detected. This 
weak signal was assigned to the naturally occurring ROS undergoing a reaction with ACP. A higher 
typical nitroxide radical signal was detected for HeLa cells treated with nanoreactors without 
illumination. The higher signal could be explained by the fact that the cells are under stress due 
to the uptake of the nanoreactors. The increase of the intracellular ROS level had no significant 
influence on the cell viability as already shown (figure 18), and therefore the level of ROS 
produced by the presence of nanoreactors in the absence of light was not sufficient to induce cell 
death. Under illumination conditions the intracellular ROS level increased if cells previously had 
taken up nanoreactors. As the spin count reflecting the amount of nitroxide radical formed 
increased from 2.65 * 108/mm3 at time point 0 min to 89 * 108/mm3 after 10 min and 105 * 
108/mm3 after 25 min irradiation with visible light, we interpretet that this significant increase 
was the trigger for the increased toxicity observed after illumination. 
Despite the increase in ROS levels in the presence of nanoreactors, only the combination of light, 
oxygen and the encapsulated photosensitizer was able to induce any significant cell death. 
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Figure 19 Development of the ESR signal (left) and the integrated intensities (right) with time. 1 are control cells with ACP. 2, 3 and 4r are after 0, 10 and 25 minutes illumination with daylight. The increased signal of 0 minutes illumination compared to the control cells may reflect cells stress due to the uptake of the nanoreactors, but the ROS level is not yet toxic taking other measurements into account.  
3.14. Laser light induced ROS production 
Laser light was used to localize RB-BSA within the cell and to stimulate the photodynamic activity 
of RB-BSA. This laser light of 543 nm was only a bit shifted from the optimal excitation wavelength 
of RB-BSA (560 nm). By using a laser light instead of artificial daylight, the light energy can be 
more focused and less energy gets lost due to absorbance of others biomolecules in the cell. 
Additionally, with this laser light the nanoreactors can be precisely stimulated within the cells and 
locally closed nanoreactors (within a few µm) are not stimulated. This experiment was designed 
to exploit the unique property of photodynamic therapy, externally activating a nanoreactor 
taken up by HeLa cells. 
Cells pre-incubated with RB-BSA loaded nanoreactor were illuminated for up to 30 minutes with 
a laser intensity of 23.7 J cm-2. The PDT light intensity normally used for treatment in clinical 
settings is between 30 and 135 J cm-2, which is a bit higher than the dose we used in our 
experiment. After only few minutes of treatment with 543 nm laser light, cells started to form 
blebs on their membrane. Such blebs are known to be triggered by PDT85. These blebs are part of 
the apoptosis process of the cell and therefore an indicator that cell is dying. Similar phenomena 
were reported after 24 h after PDT treatment, but we observed blebs formation already after 
only 5 minutes. The bleb formation could be amplified by a longer illumination time. 
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Figure 20 CLSM images of HeLa cells treated with RB-BAS loaded nanoreactors, where the membrane (green, stained with Cell Mask Deep Red 5 µg ml-1 for 5 min) and the DNA (violet, stained with Hoechst 33342 10 µg ml-1 for 10min) were fluorescently labelled. (A) HeLa cells after 24 h incubation in presence of nanoreactors, where the RB-BSA showed a fluorescent signal, which is represented in red color. The cells were nicely attached on the surface and were only minimally exposed to 543 nm light due to image recording reasons. In images (B) only the green fluorescent channel was recorded, while previously the cells had beed illuminated for 4 minutes with 543 nm laser light. The micrograph was taken 6 min after the first exposure to 543 nm laser light. After a total 5 minutes exposure to 543 nm light and 30 minutes after the first light stimuli the cells had created large blebs (C). After zoom out (D) in the treatment area (with square) the cells showed the typical blebs, while outside the illumination area, the cells were not damaged. Scale bar 20 µm (A, B and C) and 50 µm (D) 
When cells exposed to loaded nanoreactors were illuminated with laser light, abundant bleb 
formation was observed. In control experiments, cells without nanoreactors were illuminated for 
30 min and no cell damages were observed. If nanoreactors treated cells were stimulated with 
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405 nm or 633 nm laser light, they also kept their shape and integrity. This control experiment 
further supports the selectivity of PDT treatment. By controlling two out of three components 
(oxygen, light and photosensitizer), local therapy is made possible. Cells neighboring those 
treated by photodynamic therapy using laser light showed no damage. This observation indicates 
that the precision of PDT in vitro is within a few µm and provides further support that the 
nanoreactors system is working in a Trojan horse manner, by activing “on demand”. 
For comparison, HeLa cells with exposed to A1 based nanoreactors only illuminated with daylight 
were scanned by CLSM. Using the MTS assay it was shown, that cell toxicity could be induced 
within 25 minutes. CLMS micrographs supported the toxic effect, although less markedly than 
using laser light (see figure 21). Blebs were also localized, although it is possible that some of the 
blebs were removed when preparing the cells for these CLSM measurements. Importantly, some 
blebs were still visible. Moreover, no toxixity difference due to the different sized nanoreactors 
was observed. 
50 m50 m 50 m  
Figure 21 CLSM micrograph of HeLa cells incubated with A1-50 (A) A1-100 (B) and A1-200 (C) nanoreactors and after illumination with 25 minutes daylight (75 J cm-2). The red arrows indicating to bleb formation due to photodynamic activity of the nanoreactors. 
3.15. Conclusion  
We succeeded in encapsulating a photodynamic active molecule in polymersomes to create a 
nanoreactor as source of intracellular ROS on demand. We optimized the encapsulation of RB-
BSA in different PMOX-PDMS-PMOXA and PNVP-PDMS-PNVP polymersomes to obtain a high 
loading efficiency. By conjugating RB, which is a highly active photosensitizer, to BSA we increased 
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the solubility and additionally avoided interaction of RB with the polymer membrane. Therefore 
we ensured that no RB was attached to the polymersome surface, which could lead to an immune 
response. The conjugation of RB to BSA lowered the photodynamic efficiency marginally, but the 
obtained therapeutic results in vitro remain promising compared to other photoactive molecules. 
The encapsulation inside the nanoreactors had no influence on the photoactivity of RB-BSA and 
did not present  a barrier for the radicals generated in situ. The produced ROS could cross the 
polymeric membrane, while RB-BSA stayed entrapped in the aqueous core. The entrapment of 
RB-BSA inside the aqueous core of the polymersomes has various advantages: i.) protects RB-BSA 
from degradation factors ii.) increases the amount of photosensitizer that can be brought into 
cells at once and iii.) decreases possible side effects occurring from RB toxicity. 
The encapsulation efficiency likely depend on the ability to form polymersomes in solution. 
Therefore the best polymersomes regarding encapsulation efficiency were taken and compared 
in vitro. The sizes of these polymersome were in the range of 200 nm in diameter, which is optimal 
to fulfil conditions for enhanced permeability and retention effect. All of the nanoreactors were 
taken up by HeLa cells, while not showing any toxic effect under dark conditions. 
The stability of these nanoreactors in cells was also explored and no release of doxorubicin was 
observed within 24 after uptake of the nanoreactors. Therefore these nanoreactors did not 
release their content but stayed intact as a Trojan horse inside the cell waiting to be activated by 
an external stimulus. If irradiated with the proper wavelength, these Trojan became rapidly 
activated and produced ROS as long as illuminated. By measuring the intracellular ROS level, we 
found that we could increase the intracellular ROS level by a factor of 40x within 25 minutes under 
PDT illumination conditions. Along with the increasing ROS content a reduced viability was 
observed with MTS assays. Additionally we found that cells around the illuminated area were not 
affected by apoptotic bleb formation, indicating that only the combination of light Trojan horse 
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and oxygen was effective. Conversely – under dark conditions – cells survived treatment even in 
presence of these cellular Trojan horses. 
The use of light as trigger for ROS production leads to a system that which can be turned on and 
off externally, providing an intracellular source of ROS “on demand”. The efficiency of such a 
system, as shown on planar cell culture – as described here - might not be easy to extrapolate to 
a tissue, although the problem of delivering enough light to the Trojan horses for efficient activity 
can be solved by exchanging the photosensitizer. For a deeper penetration of light into tissue, 
light with lower energy has to be used. The advantage of this Trojan horse system is that the 
photosensitizer can be exchanged and optimized for application. The shell of the Trojan horse – 
the polymersome – is less exchangeable, as other systems may not be permeable to ROS or induce 
some toxic effects. 
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4. Enzymatic activity measurements in crowded nanoreactors 
4.1. Enzyme kinetics 
A nanoreactor is depending on an active molecule inside. Besides a photoactive dye, also different 
enzymes can be encapsulated and their activity in a crowded like environment can be determined. 
The activity of encapsulated, and free enzyme can be determined spectrophotometrically by 
following the concentration of produced products. Enzymes and their selective reaction are 
essential for running the metabolism in living organisms. Enzymes are in most cases built out of 
amino acid connected with each other’s forming a 3D-structure. Some enzymes use cofactors 
such as ions to assist the catalysis. 
A simple enzyme reaction equation is 
 
Where E is the Enzyme, S the substrate ES the Enzyme substrate complex and P the product of 
the reaction. This is a simplified equation assuming no back reaction after formation of the 
reaction product86. The kinetics of such a reaction can be described in a general form as: 
ݒ = ݇௖௔௧ [ܧ଴][ܵ]ܭ௠ + [ܵ] =
௠ܸ௔௫[ܵ]ܭ௠ + [ܵ] 
Where v is the reaction rate, kcat the catalytic number, [E0] the enzyme concentration, [S] the 
substrate concentration, Km the Michaelis-Menten constant and Vmax the limiting rate. In this 
equation the two fundamental parameter describing enzyme kinetics are present: kcat, which 
describe the catalytic cycles an enzymes undergoes in a certain time and Km a parameter for the 
affinity of the substrate to the enzyme86. 
If the initial enzyme concentration [E0] is unknown Km still can be determined using a double-
reciprocal plot (Linewaever-Bruk plot), where the reciprocal of the initial velocity of an enzyme 
reaction is plotted against the invers initial substrate concentration, leading to a straight line. The 
interaction of the resulting line with the x-axis is equal to -1/Km, whereas the intercept is equal to 
1/Vmax. 
A well-studied and characterized enzyme is horseradish peroxidase (HRP)87. The mainly used HRP 
isoenzyme C is a polypeptide having 308 amino acids and a molecular weight of approximately 44 
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kDa. It has a heme as cofactor, which is responsible for the catalytic activity, in which also H2O2 is 
involved.  
 
Figure 22 Reaction mechanism of Amplex Red to resorufin in presence of HRP and H2O2. 
In Figure 22 is a model reaction shown catalyzed by HRP. Amplex red is oxidized in the present of 
H2O2 and HRP to the fluorescent resorufin with the excitation wavelength of 475 nm at the 
emission wavelength of 490 nm. Therefore the production of resorufin can be followed and is 
directly proportional to the product of the reaction. Via this fluorescent measurement the 
enzymatic kinetic can be observed directly. 
4.2. Enzymatic reaction in a crowded environment 
In a living organism the enzymatic reaction are influenced by crowding agents, which are known 
to influence the enzyme kinetics88,89. The cytosol of a cell is composed of different 
macromolecules as proteins, nucleic acid or sugars, which have a concentration up to 200-400 
g/L90,91. Computational simulations already have shown that these macromolecules can influence 
the enzyme kinetic. Therefore Km determined in a buffer system without crowding molecules does 
not represent the real condition an enzyme is working. A systems to understand the enzyme 
(horseradish peroxidase (HRP)) has been investigated in different crowding milieu as entrapped 
in an agarose hydrogel92 or in the presence of dextran89. In both cases, the presence of crowding 
molecules affects the Michaelis-Menten constant, which is a parameter indicating the affinity of 
the enzyme towards its substrate, has changed. For such enzymatic reaction in a crowded 
environment mainly highly soluble macromolecules, such as Ficoll, PEG or dextran, are used to 
mimic a cellular environment 88. The use of crowding agent for sure is not an exact replacement 
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for cytosol, but is an approach to get a better understanding of the enzyme kinetic in a more 
complex system. 
4.3. OmpF 
A nanoreactor is only working if the substrate can enter and the product of the reaction can leave 
the inside of the nanoreactor. ROS was able to penetrate the PMOXA-PDMS-PMOXA membrane 
without further help. To guarantee the exchange of substrate for an enzymatic reaction, the 
membrane has to be designed more permeable. 
Nature is using membrane proteins to allow the exchange of molecules across a membrane. It 
was already shown that is possible to reconstitute different membrane proteins in a polymeric 
membrane48. We used for our purpose OmpF, as it is a channel membrane protein, which allows 
passive diffusion of molecules. OmpF unselectively let molecules up to 600 Da diffuse through its 
pore 93,94. In nature it appears as trimer with single units of about 39 kDa. It is grown in E. coli 
bacteria and extracted for reconstitution. 
4.4. Reconstitution of OmpF into polymeric vesicle membranes. 
Nanoreactors were prepared with the film rehydration method, while OmpF was added in a 
detergent containing solution during film rehydration. The hydrophobic character of OmpF 
matches with the hydrophobic environment of PDMS block in the polymeric membrane, which 
offers a similar condition as in a lipid bilayer. A successful reconstitution of membrane protein in 
a polymer membrane depends on two parameters, the thickness and the hydrophobic nature of 
the polymeric membrane95. OmpF insertion in the polymersome membrane increases the 
permeability of the PMOXA-PDMS-PMOXA membrane. Without a membrane protein the 
permeability of the membrane is restricted to a few molecules e.g. ROS46,70. 
4.5. Nanoreactor formation 
A crucial step in the nanoreactors formation is the rehydration of the polymer film. During this 
time the membrane protein gets reconstituted in the polymeric film and the active molecule will 
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be encapsulated. As the encapsulation is a statistically process not all active molecules will be 
entrapped in the nanoreactors. Hydrophilic molecules can be better entrapped in the aqueous 
core of the nanoreactor as hydrophobic ones in the membrane. Hydrophobic molecules can also 
interfere with the polymeric membrane and can prevent the self-assembly process. Due to high 
encapsulation degree the presence of the guest molecules influenced the self-assembly behavior. 
Nevertheless, we succeeded to preserve the self-assembly process in presence of up to 30 mg/ml 
Ficoll or PEG 3000 in PMOX-PDMS-PMOXA nanoreactors. Beside PEG and Ficoll, also BSA was 
needed to be encapsulated in higher –amounts for the Trojan horse project, but at a limit of 20 
mg/ml BSA –RB was the maximum that did not influence the self-assembly behavior. Higher 
concentrations of the crowding agents PEG and Ficoll were not used as the self-assembly process 
did not occur any longer. This could be either due to the increased viscosity or the interaction 
between the crowding molecules and the polymers was interfering the self-assembly process. To 
avoid a large size distribution the crowded nanoreactors were extruded through a 200 nm pore 
size membrane.  
4.6. Nanoreactor purification 
As during the self-assembly process not all molecules were encapsulated in the aqueous cavity of 
the nanoreactors, free molecules had to be separated. To achieve this size exclusion 
chromatography (SEC) was used. Compared to dialysis SEC is a faster process and therefore a loss 
of enzymatic activity due to time issue of the encapsulated active molecules could be reduced or 
even avoided. 
The column packing material was chosen according to the molecular weight of the encapsulated 
molecules. For proteins and enzymes Sepharose 2B was the preferred material, whereas for dyes 
and other small molecules Sephadex G-25 was used. The separation process was followed by UV 
absorbance measurements and the nanoreactors were separated according to their UV 
absorbance. In the first fraction the nanoreactors and other polymeric superstructures could be 
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observed, while in the following peaks the not encapsulated molecules were detected. As optimal 
volume of the separation gel 20 – 25 ml was used. This volume guaranteed separation of vesicular 
structures as the nanoreactors from the smaller free crowding agent molecules. Additionally, if 1 
ml of freshly prepared nanoreactors solution was applied on the column, it lead to an 
approximately dilution of 1:2. Therefore the polymer concentration was reduced from starting 
with 5 mg/ml to about 1.66 mg/ml. This value was taken for following calculation of polymer 
concentrations. 
As mobile phase of the column the same buffer as the rehydration one was used. As the 
reconstituted OmpF allowed the exchange of ions across the nanoreactor membrane, no special 
treatment was done to avoid different osmolality inside and outside the nanoreactor. The buffer 
was chosen according to the need of the enzymatic reaction, to obtain a high and specific signal 
from the enzymatic conversion of the added substrate.  
4.7. Nanoreactor characterization 
To assess the characteristic parameter of the nanoreactors generated for testing enzyme activity, 
LS and TEM measurements were performed. Knowing that the nanoreactors have a narrow size 
distribution the influence of the nanoreactor size on the enzyme kinetic can be minimized. 
4.7.1. Light scattering 
Light scattering studies were performed for all nanoreactors to determine Rh and Rg and ρ factor. 
Light scattering data were calculated using ALV/Static & Dynamic FIT and PLOT program version 
4.31 10/10. 
 
 
Table 4 Light scattering date of HRP containing nanoreactors and nanoreactors formed in the present of crowding agent 
 Rg  (nm) Rh (nm) Mw g mol-1 A2 mol dm3g-2 Rg/Rh 
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ABA empty 144  136  1.55 x 109 5.35 x 10-10 1.05 
ABA 30 mg Ficoll 145  136  1.24 x 109  4.98 x 10-10 1.07 
ABA 30 mg PEG 146  141  1.52 x 109 5.36 x 10-10 1.04 
 
Extrusion reduced the size distribution of the nanoreactors, but the diameters of the 
nanoreactors were higher than the pore size of the extrusion filters. The nanoreactors possess a 
certain flexibility, so that their real size is larger than the pore diameter. Still extrusion removed 
aggregates or to larger vesicles. The size distribution and low polydispersity index also indicates 
that no aggregation in solution was occurring. Furthermore, it indicates that the nanoreactors as 
we prepared them, are stable and do not fall apart. Free enzymes or crowding molecules would 
may also interfere with the light scattering signal and show a peak in the range of few 
nanometers. 
The obtained ρ-value (see table 4) are close to one. As an Rg/Rh value of 1.0 is the value for an 
ideal hollow sphere 52, the measured objects can be regards as hollow spheres, which is the 
equivalent of a vesicular structure.  
 
4.7.2. Transmission electron microscopy 
TEM micrographs were taken to support the light scattering data. The micrographs show 
spherical, but collapsed structures. This suggests that the vesicles were before hollow and 
collapsed during the TEM-sample preparation. Compared to light scattering, the nanoreactors 
have to be pre-treated before pictured by TEM. This explains not only the collapse structures but 
maybe as well the small differences in sizes. 
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In the TEM images the nanoreactors do not form aggregates and appear as individual objects. 
This is caused by the pre dilution before preparing for TEM picture but as well from the repellent 
function of PMOXA. 
   
Figure 23 (left) Overview of ABA TH nanoreactor with encapsulated HRP and reconstituted OmpF and (right) zoom view of the collapsed nanoreactor structures. The sizes are in the range of 200 nm which was already proven by light scattering data. 
 
4.8. Encapsulation Efficiency 
An important factor for the characterization of nanoreactors is their content of active substance 
and the crowding agent. The crowding concentration within the nanoreactor will have a direct 
effect of the kinetic measurements, as the presence of crowding molecules is able to influence 
the enzymatic kinetic.  
Due to the nature of molecules encapsulated, different techniques have to be used to obtain the 
information of about the EE%. The encapsulated molecules range from small one, like PEG 3000 
to larger as Ficoll or proteins/enzymes. As they are also encapsulated in different concentrations 
(2 mg/mL HRP or 30 mg/mL crowding agent), also other detection limits are applicable. As PEG 
3000 and Ficoll are not fluorescent or do not absorb UV-Vis different then the nanoreactor’s 
polymer, the change in the viscosity was used to calculate the encapsulation efficiency for PEG 
3000 and Ficoll. The encapsulation efficiency of HRP could not be determined directly by a 
spectroscopic method as the signal was too low to be detected with the used instruments. By 
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fluorescent labelling of the enzyme the detection limit could be lowered and the signal was better 
distinguishable from the polymer absorbance. By using FCS the average number of HRP per 
nanoreactor was evaluated.  
4.8.1 Crowding agents 
The encapsulation efficiency of Ficoll and PEG was measured by ESR. By co-encapsulating a spin 
probe (5 doxylstearic acid (5 DSA)) together with the crowding agent, PEG and Ficoll respectively, 
their intra vesicular concentration was determined in situ without modifying the crowding agent 
or destroying the nanoreactors. The ESR spectra of 5 DSA in 0.1 M NaOH, in empty vesicles, in 
vesicles loaded with PEG and in free PEG solution (with concentration of 60 mg/mL in water) were 
measured and are shown in Figure 24. As indicated in Figure 24 free 5 DSA in water shows a typical 
isotropic triplet with no additional broad signal caused by aggregation and an aN value of 15.8 G 
similar with the values reported in the literature96. In case of 5 DSA encapsulated in empty vesicles 
the obtained spectrum presents an anisotropic spectral pattern with the parallel and 
perpendicular hyperfine components well separated, similar with that described in literature for 
lipid bilayers97, indicating that the nitroxide probe is immobilized in the vesicles membrane.  
In the presence of 60 mg/mL PEG the obtained spectrum shows the typical isotropic triplet, 
indicating the free rotation of the spin probe. A broader high-field line characteristic for the 
nitroxide group indicates the increase in the local viscosity, due to the PEG presence, comparing 
with 5 DSA measured in 0.1 M NaOH. For 5 DSA encapsulated in PEG loaded vesicles a more 
complex signal was detected containing both anisotropic spectral pattern due to entrapment in 
the membrane siloxane layer and the typical isotropic signal indicating a higher mobility 
component as observed in both 0.1 M NaOH or the 60 mg/ml PEG solution. The isotropic 
component of the ESR signal detected in loaded vesicles was assigned to encapsulated 5 DSA in 
aqueous compartment of the nanoreactors, and was further employed to determine the rotation 
correlation time (τc), corresponding to PEG solution encapsulated in nanoreactors. 
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Figure 24 ESR spectra of 5 DSA in PEG aqueous solution, in PEG loaded and empty vesicles and in 0.1 M NaOH 
To determine the average concentration of the crowding agent inside the nanoreactors τc was 
determined from the experimental ESR spectra of 5 DSA recorded in PEG solutions of increasing 
concentrations (from 0 mg/mL up to 30 mg/mL) and nanoreactors. τc for the 5 DSA in NaOH was 
determined as 0.77 nsec similar to literature values98. In presence of higher PEG concentration τc 
increased linearly from 0.91 nsec for 0.5 mg/mL PEG to 2.84 nsec for 30 mg/mL PEG (standard 
curve) as shown in Figure 2. 
τc for the 5 DSA in PEG loaded polymer vesicles (for PEG initial concentration of 30 mg/mL) was 
determined as 2.27 nsec, corresponding for an intra-vesicular PEG concentration of 21 mg/mL as 
obtained from the corresponding standard curve depicted in figure 24. 
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Figure 25 Standard curve for the dependence between PEG concentration and τc of 5 DSA dissolved in increasing PEG concentrations. 
The same experiment was repeated using 20 mg/mL, respectively 10 mg/mL PEG as 
starting concentration during the film rehydration. The determined τc for encapsulated 5 DSA in 
the corresponding two types of nanoreactors was determined as 1.79 nsec (for 20 mg/mL PEG), 
and 1.19 nsec (for 10 mg/mL PEG) corresponding to a final concentration of encapsulated PEG 
inside nanoreactors of 13.3 mg/mL, respectively 4.1 mg/mL. 
A similar behavior was observed in case of 5 DSA in the presence of Ficoll and polymeric 
vesicles loaded with Ficoll shown in figure 3. For 5 DSA encapsulated in Ficoll loaded vesicles a 
more complex signal with two different components (one broad signal characteristic for low 
motion spectra due to the encapsulation in nanoreactors membranes and one isotropic due to 
the encapsulation inside the nanoreactors) was detected, similar to nanoreactors encapsulating 
PEG. 
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Figure 26 ESR spectra of 5 DSA in Ficoll aqueous solution, and in Ficoll loaded polymeric vesicles. 
A standard curve for 5 DSA in presence of Ficoll was obtained (figure 26), by plotting the τc value 
of 5 DSA determined in the presence of increasing Ficoll concentrations (from 0.5 to 50 mg/mL 
Ficoll), against Ficoll concentration. τc values determined for the isotropic component of the ESR 
signal recorded in nanoreactors were further compared with the standard curve and Ficoll 
concentration was evaluated. τc for 5 DSA in Ficoll loaded polymer vesicles (when Ficoll starting 
concentration was 30 mg/mL) was determined as 1.25 nsec, corresponding for a Ficoll 
concentration of 9.3 mg/mL. In case of loaded nanoreactors with 10, respectively 20 mg/mL 
starting concentration τc of 5 DSA was determined as 0.93 and 0.97 nsec, corresponding to a local 
concentration of 2.1 mg/mL and 2.8 mg/mL Ficoll, as shown in Figure 26. 
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Figure 27 Standard curve for the dependence between Ficoll concentration and τc of 5 DSA dissolved in increasing Ficoll concentrations. 
Table 5 Crowding agent concentration inside the nanoreactor and its corresponding viscosity 
Starting 
concentration 
Viscosity 
Ficoll 
Viscosity 
PEG 
Ficoll 
concentration 
Viscosity PEG concentration Viscosity 
10 mg/ml 1.018 
m2s-1 
1.022 
m2s-1 
2.2 mg/ml 0.932 m2s-1 4.1 mg/ml 0.942 m2s-1 
20 mg/ml 1.129 
m2s-1 
1.158 
m2s-1 
2.8 mg/ml 0.938 m2s-1 13.3 mg/ml 1.067 m2s-1 
30 mg/ml 1.240 
m2s-1 
1.293 
m2s-1 
9.3 mg/ml 1.010 m2s-1 21.0 mg/ml 1.171 m2s-1 
 
The encapsulation efficiency (EE%) was determined as 14 – 31 % for Ficoll 41 % and 70 %. For PEG 
the more than 20 times smaller PEG molecule (3 kDa) was better entrapped as the larger Ficoll 
dendrimer (70 kDa). 
4.8.2. Enzyme encapsulation efficiency 
 HRP was either encapsulated alone or together with the crowding agent. To determine the 
number of HRP per nanoreactors, HRP was labelled using a labelling kit from life technologies, 
which labels proteins with Oregon Green®. With an amine-reactive fluorophore a stable covalent 
bond to a protein can be established. Not reacted fluorophore can be removed with a separation 
step, while the degree of labelling can be determined spectrophotometrically. The degree of 
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labelling was 0.7, sufficient enough to determine the encapsulation efficiency for HRP. The 
diffusion time determined by FCS correlated with the size of the fluorescent labelled molecules 
or particles, was further used to assess the successful encapsulation of HRP molecules inside 
nanoreactors. Labelled HRP and encapsulated fluorescent molecules shows larger diffusion times 
than the free dye99,100. The diffusion time measured with FCS increased from 48.8 µs for free 
Oregon Green to 256 µs for the labelled HRP. Encapsulation of HRP in vesicles with and without 
crowding agent increased the diffusion time up to 2555 µs for no crowding agent and 2607 µs 
and 2515 µs for Ficoll respectively PEG loaded nanoreactors. The diffusion times were obtained 
using a three component fitting, showing that no minor population for free dye or labelled HRP 
were present after purification.  
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Figure 28 Normalized FCS autocorrelation curves for Nanoreactors loaded with labelled HRP, labelled HRP and free Oregon Green and the corresponding fitting curves. 
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Table 6 Data obtained from FCS measurement, where values marked with * are fixed, so that only one component could be determined per measurement. 
 Count rate [kHz] CPM [kHz] C1 [µs]  C1 % C2 [µs] C2 % C3 [µs] C3 % 
Oregon green 77 13.2 48.8 100     
Oregon Green in PEG 77 15.2 53.2 100     
Oregon Green in Ficoll 76 14.7 53.8 100     
HRP labelled 22 10.7 *48.8 70 265 30   
ABATH encapsulating labelled HRP 18 36.5 *48.8 ≈0 *265 ≈0 2555 100 
ABATH Ficoll encapsulating labelled HRP 
26 39.0 *48.8 ≈0 *265 ≈0 2607 100 
ABATH PEG encapsulating labelled HRP 
8 36.5 *48.8 ≈0 *265 ≈0 2512 100 
 
Comparing the brightness of the particles measured by FCS (free dye and nanoreactors) number 
of HRP per vesicles was calculated. In all cases (with and without crowding agent) the numbers of 
HRP per nanoreactors is in average between 3 and 4. FCS measurements and the resulting 
encapsulation efficiencies show that the crowding agents do not influence the encapsulation 
efficiency of HRP. Nevertheless, due to the low degree of labelling and the uncontrolled self-
assembly processes, there is the theoretical possibility to have none enzyme in a vesicles or to 
have more the 4 enzymes per vesicles. The amount of HRP per nanoreactor is in good agreement 
with other similar system and labelled enzymes101,102. 
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The encapsulation efficiency of HRP, if compared with the starting concentration, is between 9.7% 
and 11.2%. This is in the typically range for PMOXA-PDMS-PMOXA based nanoreactors produced 
by film rehydration49,51,69,102. 
The simplest way to calculate encapsulation efficiency is by comparing the initial concentration 
with the concentration encapsulated. This was mainly done for encapsulation of RB-BSA, as RB-
BSA could not be detected with FCS. A dependence in encapsulation efficiency depending on 
polymer properties or nanoreactor size could not be observed. At low initial concentration the 
encapsulation efficiency was around 13 % and lower, depending on the ability to form vesicles. 
Encapsulation of macromolecules at a high initial concentration (>10mg/ml) several small trends 
could be observed. PEG 3000 was better encapsulated in the nanoreactors as the almost ten times 
bigger Ficoll macromolecule. 
It was also observed that the encapsulation efficiency is depending on the starting concentration 
if (C0 ≥ 10 mg/ml). For both Ficoll and PEG 300 the encapsulation efficiency is higher if the 
concentration used in the rehydration mixture is higher. An explanation for this is, that higher the 
initial concentration is higher the chance induced by crowding molecule it gets. 
4.9. Enzymatic activity in the nanoreactors 
HRP is one of the best characterized enzymes which have found various application in industry, 
science and even medical applications 87. In literature, the reaction with amplex red under similar 
conditions as we have performed our kinetic measurement, the value of the Michaelis-Menten 
constant is around 81 µM103. To avoid difference coming from experimental details we have 
performed enzymatic reaction for different situations (crowding and encapsulation) under the 
same condition (buffer, temperature, H2O2 concentration and Amplex red concentration). To 
exclude pipetting errors of small volumes enzymatic reaction were performed in a multi-well 
plate to perform several kinetic runs in parallel. 
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In a first trial the kinetic of free HRP in bulk in the absence of crowding molecules was done and 
a Km value of around 55 µM , close to the value already reported was obtained. By adding Ficoll 
or PEG up to concentrations of 30 mg/mL in 10 mg/mL steps we observed that Km values were 
influenced by the presence of the crowding agent. In case of Ficoll the Km value was around 31 
µM for all three measured crowding agent concentrations. In the presence of PEG the Km value 
decreased even more around 25 µM. This already shows that the crowding agent has a dramatic 
influence on the kinetic of an enzyme. In our case, the crowding agent had not only induce a 
decrease of the Km value, but also a different behavior has already been reported for other 
enzymes 88,104. A decrease of the Km value from 55 µM to 31 µM, 25 µM respectively, means that 
the enzyme-substrate affinity is almost doubled. Due to the presence of the crowding agent, the 
substrate has less space in the aqueous phase and the possibility to interact with the active side 
of HRP can be increased. Additionally the crowding molecules can have a positive effect on the 
stability of the enzyme or the substrate during the reaction, but experiments in this direction 
were not performed. 
0 5 10 15 20 25 300
5
10
15
20
25
30
35
40
45
50
55
60
65
 Free conditions Encapsulated
Km
 [µM
]
Initial Ficoll concentration [mg/ml]
0 5 10 15 20 25 30
0
5
10
15
20
25
30
35
40
45
50
55
60
65
 Free conditions Encapsulated
Km
 [µM
]
PEG concentration  
Figure 29 (left) Michaelis-Menten constant of HRP in the present of different Ficoll concentrations (black) and encapsulated with different Ficoll concentrions (red). (right) Michaelis-Menten constant of HRP in the present of different PEG 300 concentrations (black) and encapsulated with different Ficoll concentrions (red). 
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4.10. Conclusion  
A successful combination of biologicals entities and synthetic materials is still a challenge for 
diagnostic purpose or engeneering devices at the nanometer scale [Baumann_2011]. By 
reconstitution of the membrane protein in a polymeric membrane and simultaneously 
encapsulating an enzyme, shows that hybrid material (synthetic-biologic) can have great 
opportunities to answer scientific questions or to help increasing efficiency and stability of an 
enzyme. A still not completely solved question is the one of enzymes kinetic in cellular conditions. 
With the encapsulation of enzymes in nanoreactors we tried to simulate an artificial organelle 
and additionally tried to mimic a crowded environment with macromolecules to get a better 
understanding of enzyme kinetics under cellular conditions. 
The use of a high density of macromolecules affects the self-assembly process of nanoreactors 
which shows that there are limitations for the self-assembly process. In the presence of 30 mg/mL 
macromolecules it is still possible to form self-assembled nanoreactors while reconstituting OmpF 
and encapsulating HRP, while at higher concentartion the self-assembly process is not occuring 
anymore in a proper way to obtain nanoreactors. 
The concentration of macromolecules inside the nanoreactors is not equal to the macromolecular 
concentrations of the rehydartion solution. Comparing the concentration inside the nanoreactors 
with the concentration before the encapsulation, we have seen that smaller macromolecules (3 
kDa) have a better efficiency to be entrapped as larger (70 kDa). Using the same starting density 
(in mg/mL) of the macromolecules the smaller molecules have double the density in the 
nanoreactors as the larger one. Also the enzymes as a larger macromolecule (44 kDa) showed 
encapsulation efficiencies around 10% or 3-4 enzymes per nanoreactor. 
We showed that the enzyme kinetic is not only affected by the crowding molecules PEG and Ficoll, 
but as well by the restricted space in the aqueous cavity of the nanoreactor. This system is maybe 
far of simulating cellular conditions, but represent a smart approach to show the influence of 
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crowded environment and confined space. The activity of the enzyme can be tuned due to 
encapsulation and crowding agent, which may in some cases improve enzyme activity. Such a 
crowded nanoreactor can also be considered as a further step towards an artificial cell or 
organelle, as the enzyme was compartmentalized but still interacting with the environment 
through the channel proteins. 
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5. General conclusion and outlook 
As it was shown within this thesis the possibility of using polymersomes can have great 
advantages compared to existing methods. Nevertheless both systems can still be improved and 
have to be further tested for a real applications. The enzymatic assays have to be repeated with 
other enzymes or other substrate to see if the system is also working under these conditions. For 
the Trojan horse a sterile way of producing the polymersome has to be found, so that a next step 
of in vivo studies can be performed.  
By synthesizing different block ratio of the polymers there can be found maybe a more optimal 
polymersome structure for the applications, but this has to be done with try and error, as the 
Trojan horse experiment have shown, there is no specific trend comparing block ratio and 
encapsulation efficiency or polymersome formation. 
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6. Materials and Methods 
Materials 
Materials were ordered from Sigma Aldrich id not further noticed and used without further 
treatment. 
Rose Bengal-BSA conjugation51 
20 mg (300 µM) bovine serum albumin (BSA) was dissolved in 1 ml PBS solution containing 100 
µM Rose Bengal (RB). After 1 h at room temperature the solution was applied on a 
HiTrapDesalting column containing Sephadex™ Superfine (GE Healthcare, UK). The successful 
conjugation can be followed using UV-Vis spectroscopy recording 550 nm and 560 nm.  
Vesicle formation51 
The synthesis and characterization of PMOXA-PDMS-PMOXA and PNVP-PDMS-PNVP polymers 
used for these studies is described elsewhere. For the formation of polymeric vesicle film 
rehydration method was used. First the polymer was dissolved in pure ethanol. Afterwards 5 mg 
of dissolved polymer was added to a 25 ml ethanol-cleaned round-bottom flask and ethanol was 
evaporated at a reduced pressure of 150 mbar in a rotary evaporator (Büchi Rotavap R-124 with 
vacuum controller B-721, Büchi, Switzerland) at 40°C while rotating at 100 rpm for 30 min to 
obtain a polymer film on the inner glass surface of the flask. In a final step pressure was reduced 
to 100 mbar for an additional 5 min. 
The encapsulating solution was premixed and the volume was adjusted to 1 ml. The solution was 
added to the 25 ml round-bottom flask with the polymer film and stirred overnight under 
atmospheric pressure. The film rehydration was performed at room temperature or at 4°C 
depending on the stability of the encapsulating molecules. The flask was tilted, so that the whole 
polymer film was detached from the glass surface. 
To obtain uniform size vesicles, the rehydrated solution was extruded with a LipoFast-Basic 
extruder (Avestin, Canada) through a 0.2 µm Track-Etch membrane (Whatman, UK). If necessary 
other filter membranes (0.4 µm, 0.1 µm and 0.05 µm) were used. After extrusion the vesicle 
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solution was applied on a size exclusion chromatography (SEC) column filled with Sepharose 2B 
connected to an ÄKTA prime (GE Healthcare, UK). The elute was recorded using a UV detector 
(280 nm) and fractionated according to de appearing peaks.  
Light Scattering51 
Light scattering experiments were performed using an ALV goniometer (ALV GmbH, Germany) 
equipped with an ALV He-He laser (JDS Uniphase, wavelength λ = 632.8 nm). The vesicle solutions 
(1.0, 0.66, 0.5, 0.4, 0.33 mg ml-1) were measured in a 10 mm cylindrical quartz cell at angles 
ranging from 30° to 150° at 293 K. ALV/Static & Dynamic FIT and PLOT program version 4.32 10/10 
was used to analyzed the data. Static light scattering data were processed according to the 
Gunier-model. 
Transmission electron microscopy51 
10 ml empty polymer vesicle solution and an RB–BSA conjugate loaded polymer vesicle solution 
were negatively stained with 2% uranyl acetate solution and deposited on a carbon-coated 
copper grid. The samples were examined with a transmission electron microscope (Philips 
Morgani 268 D) operated at 80 kV. 
 OmpF expression and purification105 
OmpF was expressed into the host E. coli BE strain BL21 (DE) omp8 (F_hsdSB (rb_mB) gal ompT 
dcm(DE3) DlamB ompF::Tn5 DompA DompC). 
OmpF expression and purification was adapted from Nallani et. al106. An overnight culture was 
used to inoculate 1L LB medium containing 100 μg/mL ampicillin starting with an OD600 of 0.1 
(250 rpm, 37°C). Reaching an OD600 of 0.6, isopropyl-β-D-thiogalactopyranoside (IPTG) was 
added to a final concentration of 1 mM to induce expression of OmpF. Cells were grown for 
additional 4 h, following harvesting by centrifugation (10 min, 6000 rpm, 4°C). The cell pellet was 
resuspended in 10 ml lysis buffer (20 mM Tris-Cl pH 8.0, 2% SDS) per 1g of cell pellet. The 
resuspended cells were shortly sonicated and passed three times through a high-pressure 
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homogenizer at 2000 bar. Afterwards the homogenized solution was centrifuged (40 min, 22000 
rpm, 4°C) and the obtained pellet was further used 
The pellet was resuspended (0.125% octyl-POE in 20 mM phosphate buffer pH 7.4) for a pre-
extraction step and incubated for 1 h at 37°C. After an additional centrifugation step (40 mi, 40000 
rpm, 4°C) the remaining pellet was further treated with 3% octyl-POE in 20 mM phosphate buffer 
pH 7.4 for the final OmpF extraction. In a final centrifugation step (40 min, 40000 rpm, 4 °C) the 
solubilized OmpF was separated from the membranes. 
The expression and the purity were verified by SDS-PAGE (12%). The concentrations were 
determined spectrophotometrically at 260 nm and the sample stored at 4°C till use. 
Cell culturing 
Cell culture was started using a stock culture containing 1 million cells in 10 % DMSO. The stock 
culture was defrosted and diluted with culture medium (DMEM with 10% FCS and 2% Pen/Strep). 
After centrifugation (10 min at 1000 rpm, approx. 200??) supernatant was removed and fresh 
culture medium was added. Afterwards, the resuspended cells were incubated in a 75 cm2 flask 
(BD Falcon, USA) at 37° C and 5% CO2. Cells were split twice per week, removing the culture 
medium, rinsing with PBS and trypsinizing. Before that, the solution was centrifuged and the 
supernatant was removed and the cells were resuspended in fresh culture medium. Cell density 
was determined using Countess® Automated Cell Counter (Invitrogen, USA). For continuing cell 
culture 1 million cells were incubated in cell culture flask and fresh medium was added up to a 
volume of 25 ml. For experiments cells were taken and incubated on well plates for at least 24 h 
before experiments. 
Cell toxicity assay51 
2 x 104 HeLa cells per well were cultured in 200 µl fresh culture medium for 24 h in a 96-well plate. 
Afterwards medium was exchanged and the cells were incubated with different concentrations 
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of nanoreactors (50 – 500 µg/ml) keeping the volume constant. Differences in concentration were 
adjusted using PBS. After the desired incubation time the culture medium was exchanged and 20 
µl of MTS (3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-2H-
tetrazolium) assay solution (Promega, USA) was added. After 1 h incubation with MTS, the 
absorbance of each well was measured at 490 nm with a microplate reader (SpectraMax M5e, 
Molecular Devices, USA). Cell viability was calculated assuming cells grown without the presence 
of nanoreactors and background corrected with culture medium and MTS assay solution as 100% 
viable.  
Uptake studies (CLSM)51 
For microscope experiments HeLa cells were cultured at a density of 5 x 104 cells per well in a 8-
well Lab-Tek™ (Nalge Nunc International, USA) in 300 µl culture medium for 24 h to allow 
attachment to the surface. After attachment, the medium was removed and nanoreactor solution 
in DMEM growth medium without FCS was added. After the desired incubation time cells were 
stained with the desired dyes. 
Table 7 Used dyes for cell staining and its incubation time and used lasers. 
Dye Stock 
concentration 
incubation 
volume 
Incubation 
time 
Used laser Staining 
compartments 
Hoechst 
3342 
100 µg/ml 20 µl 10 min 405 nm DNA (nucleus) 
Cell mask 
Deep Red 
50 µg/ml 20 µl 5 min 633 nm Cell 
membrane 
Lysotrack 
Deep Red 
1 µM 20 µl 10 min 633 nm Acid 
compartments 
 
After incubation with dyes, cells were washed three times with PBS and let in 300 µl PBS. Cells 
were visualized using a confocal laser scanning microscope (Carl Zeiss LSM510, Germany) 
equipped with a 40x water emulsion lens (Olympus, Japan). The cells micrographs were recorded 
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in multitrack mode and the intensity of each fluorescent dye was adjusted individually. For control 
micrographs same setting were used as for sample micrographs. Carl Zeiss software (version 4.2 
SP1) was used to record and images processing. 
Uptake studies (Flow cytometry)69 
1 x 105 HeLa cells were seeded in a 24-well plate and grown for 24 h in culture medium (1 ml). 
After 24 h medium was exchanged and nanoreactor solution with DMEM growth medium was 
added. After 24 h incubation in presence polymeric vesicles cells were washed with PBS, 
trypsinized, centrifuged, resuspended in PBS and put on ice. Flow cytometry was measured with 
a BD FACSCanto II flow cytometer (BD Bioscience, USA) using FCS and SSC detectors as well as 
fluorescent channel for RB-BSA. A total amount of 20’000 events for each samples were analyzed. 
Data treatment was done using Flowing Software 2.5.0 (Turku Center for Biotechnology, Finland). 
In vitro radical measurement69 
The cell culturing was adapted from Pierzchala. 2 x 105 HeLa cells per well were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal calf serum (FCS) in a 6-well 
plate for 24h at 37°C in humidified CO2 incubator. Afterwards the cells were incubated for another 
24h in DMEM and the present of the vesicles. The cells were washed twice with PBS and then 
incubated under dark conditions at room temperature for 90 min with 10 mM 1-Acetoxy-3-
carbamoyl-2,2,5,5-tetramethylpyrrolidine (ACP) (Enzo Life Sciences, Switzerland). Afterwards the 
cell were detached and centrifuged at 1000 rpm for 5 min. The supernatant was removed and the 
cell were resuspended in 200 µl PBS and transferred into a glass pipette. 
The samples containing ACP, cells, cells and ACP, cells and RB-BSA loaded vesicles were measured 
as prepared, before and after 5-20 min irradiation. The quantitative determination was 
performed using the SpinCount and internal reference provided by Bruker with the spectrometer. 
The DMPO spin adducts were obtained by mixing 0.1 mL of 1 mM DMPO solution in PBS with 
0.5 mL Rose Bengal 4 µM RB-BSA or 0.5 mL ABA SE1 polymersomes loaded with RB.  
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ESR measurements were performed on a Bruker CW ESR Elexsys-500 spectrometer equipped 
with a variable temperature unit. The spectra were recorded at 298 K with the following 
parameters: microwave power 2 mW, number of scans up to 20, resolution 2048 points, 
modulation amplitude 0.5 G. ESR spectra were simulated using the WINSIM 2002 (NIEHS/NIH) 
simulation package[3]; that allows the determination of the hyperfine couplings line width with an 
error of 5%. 
 
Radical detection with ESR 
2,2,6,6-Tetramethyl-4-piperidinol (TMP–OH) powder was weighed and a solution with the same 
amount of RB was added to the powder to obtain a concentration of 200 mM. In the case where 
RB, RB–BSA, and the vesicle solution did not have the same absorbance at 550 nm and 560 nm, 
the sample was diluted with PBS until they all had the same RB concentration. The ESR 
experiments were carried out at room temperature using an ESP300E spectrometer (Bruker 
BioSpin, Germany) operating at the X-band frequency and equipped with a standard rectangular 
mode TE102 cavity. Samples were transferred to 0.7mmID and 0.87 mm OD glass capillary tubes 
(VitroCom, NJ, USA), with sample height _50 mm (_20 ml), and sealed on both sides with Cha.seal 
(tube sealing compound, Chase Scientific Glass, Rockwood, TN, USA). An assembly of seven tightly 
packed capillaries was bundled together and inserted into a wide-bore quartz capillary (standard 
ESR quartz tube with 2.9 mm ID and 4 mm OD, Model 707-SQ-250M, from WilmadGlass Inc., 
Vineland, NJ, USA). This setup resulted in ca. 140 ml sample volume in the active zone of the 
TE102 cavity. The samples were illuminated with visible light and measured with the typical 
instrument settings: microwave frequency 9.77 GHz, microwave power 10.1 mW, sweep width 
100 G, modulation frequency 100 kHz, modulation amplitude 0.5 G, receiver gain 2 _ 104, time 
constant 81.92 ms, conversion time 40.96 ms and total scan time 41.9 s. 
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ESR measurements for intravesicular viscosity measurement 
ESR measurements were performed on a Bruker CW ESR Elexsys-500 spectrometer equipped with 
a variable temperature unit. The spectra were recorded 298 K with the following parameters: 100 
KHz magnetic field modulation, microwave power 2 mW, conversion time 61.12 ms, number of 
scans up to 20, resolution 2048 points, modulation amplitude in the range of 0.4 G, sweep width 
100 G. The nitrogen hyperfine coupling (aN) was determined directly from the spectra for 
motional narrowed lineshapes with an error limit of 5%. The microviscosity in proximity of the 
nitroxide free-radical probe was determined by the means of the correlation time τc related to 
the rotational reorientation of the probe: 
߬௖ =  6.5 ∗ ݁ିଵ଴ ∗ ∆ܪ଴ ∗  ቐඨ ܫ଴ܫାଵ − 1ቑ 
, where ΔH0 is the linewidth of the 0 transition, I0, I+1, I-1 are the peak to peak heights of the 0, +1 
and -1 transitions.  
ESR Control experiments 
In order to determine the dependence of τc of the spin probe of concentration of both PEG and 
Ficoll, series of solutions containing 0.1 mM 5 DSA in 0.1 M NaOH and PEG in concentrations 
varying from 0.5 mg/mL to 30 mg/mL or Ficoll ranging from 0.5 mg/mL to 50 mg/mL were 
measured. τc was determined for each solution and the standard curve obtained by fitting linear 
all the points describing the dependence of τc to PEG or Ficoll concentration was obtained. 
Fluorescence labelling of HRP 
HRP was labeled fluorescently using Oregon Green ® 488 Protein Labeling Kit (O-10241) from life 
technologies and used according their protocol. The labelling efficiency was calculated according 
to the given protocol using the specific absorbance of HRP at 403 nm and the absorbance of 
Oregon Green at 496 nm. The absorbance was measured spectrophotometrical using nanodrop 
2000c (ThermoScientific, USA). 
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Fluorescence correlation spectroscopy (FCS) 
A Zeiss510/Confocor2 laser scanning microscope equipped with an argon laser (488nm) and a 40 
x water-immersion objective (C-Apochromat 40X, NA 1.2) with a pinhole adjusted to 70 µm was 
used in FCS mode to measure solution of Oregon Green, labelled HRP, and vesicles encapsulating 
labelled HRP separately at room temperature. FCS spectra were recorded over 10 s and 
measurement was repeated 30 times. For autocorrelation function and fitting LSM510/confocor 
software package version 4.2 SP1 was used, were structure factor and diffusion times of 
individually measured free dye and labelled HRP, were fixed for the fitting procedure.  
Encapsulation efficiency calculation 69 
Encapsulation efficiency of the vesicle formation process [EE%] was determined as following: 
ܧܧ[%] = ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊ ݂ܽݐ݁ݎ ݁݊ܿܽ݌ݏݑ݈ܽݐ݅݋݊ ܽ݊݀ ݌ݑݎ݂݅݅ܿܽݐ݅݋݊ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊ ܾ݂݁݋ݎ݁ ݁݊ܿܽ݌ݏݑ݈ܽݐ݅݋݊ × 100 
Therefore the absorbance of the to-be encapsulated solution was compared with the 
nanoreactors after size exclusion. Additionally the volume was corrected, to deal with the 
dilution occurring during size exclusion chromatography.  
The maximum number of RB-BSA conjugates (#RB-BSAper vesicle), which can be encapsulated per 
vesicle was calculated using: 
#RB − BSA௣௘௥ ௩௘௦௜௖௟௘ =  ܥ଴ ×  ஺ܰ ×  4 3ൗ  × ߨ × ܴ௛ଷ  × 1000 (eq. 2) 
where C0 is the concentration of RB-BSA conjugates encapsulated [mol/L], and Rh is the 
hydrodynamic radius of vesicles [m] obtained from light scattering. 
Kinetic measurement 107 
Amplex ultra red (AR) (Invitrogen, US) was dissolved in DMSO as 10 mM stock solution. A 96-well 
microplate (BD Bioscience, US) was used to perform 8 parallel kinetics measurements for each 
substrate concentration. The wells were filled up to 200 ul with PBS containing 
Nanoreactors/HRP, 2, 4, 8 or 12 µM AR and an excess of H2O2 (20 µM). The kinetic was recorded 
at 25 °C with a SpectraMax M5e (MolecularDevices, US) measuring each 20 second after shacking 
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the fluorescence signal of AR (570nm/595nm). For the calculation of the Michaelis-Menten-
constant (Km) the initial rate was determined by linear regression analysis of the slope (R2>0.99). 
Further calculations were performed by using Origin and MS Excel software packages.  
Abbraviations 
ACP   1-Acetoxy-3-carbamoyl-2,2,5,5-tetramethylpyrrolidine 
AFM   Atomic force microscope 
AqpZ   Aquaporin Z 
BSA   Bovine serum albumin 
CLSM   confocal laser scanning microscope 
CPM   counts per molecule 
Da   dalton 
DMPO   5,5-dimethyl-1-pyrroline N-oxide 
DNA   Deoxyribonucleic acid 
DOX   doxorubicin 
EE%   encapsulation efficiency 
EPR   enhanced permeability and retention effect 
ESR   Electron spin resonance 
EtOH   Ethanol 
FCS   fluorescence correlation spectroscopy 
FhuA   ferric hydroxamate uptake protein component A 
FSC   forward scattering 
h   hour 
HRP   Horseradish peroxidase 
K   Kelvin 
kcat   catalytic number 
Km   Michaelis-Menten constant 
MTS   3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
OmpF   Outer membrane protein F 
PAA   poly(acrylic acid) 
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PAGE   polyacrylamide gel electrophoresis 
PB   Poly(butadien) 
PBS   phosphate buffered saline 
PCV   polyvinyl chloride 
PDMA   poly(2-(diisopropylamino)ethyl methacrylate) 
PDMS   poly(dimethylsiloxane) 
PDT   photodynamic therapy 
PEG   polyethylene glycol 
PEO   Poly(ethylene oxide) 
PET   polyethylene terephthalate 
PLA   poly(lactide) 
PLC   poly(ε-caprolactone) 
PLGA   poly(lactic-co-glycolic acid) 
PMPC   poly(2-methacryloyloxyethyl phosphorylcholine) 
PMOXA   poly(2-methyl-2oxazoline) 
PNVP   poly(N-vinylpyrrolidone) 
PS   poly(styrene) 
RB   Rose Bengal 
Rg   Radius of gyration 
Rh   Radius of hydration 
ROS   reactive oxygen species 
SDS   sodium dodecyl sulfate 
SEC   size exclusion chromatography 
SSC   sideward scattering 
TEM   transmission electron microscopy 
TEMPOL  4-hydroxy-2,2,6,6-teramethyl piperidin-1-hydroxyl 
TEMPONE  4-oxo-2,2,6,6-teramethyl piperidin-1-oxyl 
Tg   glass transition temperature 
TMP–OH  2,2,6,6-tetramethyl-4-piperidinol 
TNF-α   tumor necrosis factor-α 
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Tsx   receptor protein for the phage T6 and colicin K 
UV   ultra violet 
Vmax   limiting rate 
°C   degree Celsius 
[E0]   enzyme concentration (at time zero) 
[S]   Substrate concentration 
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